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It is well established that athletes, including long distance runners, can be more 
prone to acute upper respiratory tract (URT) illnesses during periods of intense 
and prolonged training. Therefore, a sport and exercise medicine physician 
frequently advise on the athlete’s eligibility for participation in a sport event or 
exercise session. To date, a clinical tool called the “neck check” was utilized as a 
guideline for such advice. There are however very little evidence available in the 
literature 1) to validate this guideline, 2) predict how many runners will have 
symptoms of an acute illness one week prior to an endurance race, 3) predict 
how many runners will “fail” the “neck check” in the 7-day period before a race 
and would be advised not to participate, 4) what the influence of educational 
information and guidelines on the acutely ill athlete’s decision on participation in 
the race will be, and 5) how many runners, with an acute pre-race illness who 
choose to start the race, do not finish the race or develop medical complications 




The main objectives of this dissertation was: 1) to review the available evidence 
with respect to the period prevalence of pre-race upper respiratory tract 
infections (the week before a distance running event) in distance runners, the 
relationship between exercise and infections, and the possible health 
consequences of participating in sport whilst suffering from an acute infective 
illness; 2) to document the period prevalence of runners with an acute illness in 
the 7-day period prior to an endurance race; 3) to determine the period 
prevalence of runners who “fail” the “neck check”, and would be advised not to 
participate in the race, 4) to determine the incidence of runners with an acute 
illness, and who received educational information and guidelines, and who then 
not start the race, 5) to determine the incidence of runners with an acute illness 
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who chose to start the race, but do not finish the race, and 6) to determine the 
incidence of runners with an acute illness who chose to start the race, but 




Phase 1: Review of the literature utilizing evidence based principles 
Electronic databases were utilised to source literature relating to the 
epidemiology of acute illness in athletes, the relationship between exercise and 
the immune system, risk factors for illness, the effect illness has on exercise 
performance and various systems of the body, return-to-play guidelines for the ill 
athlete, potential medical complications when exercising with an acute illness, 
and possible preventative strategies to avoid becoming ill. 
 
Phase 2: Research study 
In a prospective cohort study, 7035 runners were recruited (5954 by email 5 days 
prior to the race, and 1085 by interviews held in the 3-day period prior to the race 
during registration at the expo). All the participants completed a pre-race acute 
illness questionnaire in which they reported if they experienced one or more 
symptoms of an acute illness in the 7-day period prior to the race. All runners 
who indicated that they experienced any symptoms (N=1338) received an 
educational information leaflet (either via email or as a hand-out at the expo). 
The leaflets contained general information about acute illness, information about 
the risk to exercise with the illness, and specific guidelines on when not to 
participate while certain symptoms are present. 
 
Based on the response to the pre-race acute illness questionnaire, the 7035 
runners were firstly categorized into an asymptomatic control group (n=5697), 
and a symptomatic group (including all the runners with any symptoms of an 
infection) (n=1338). Runners in the symptomatic group were further divided into 
sub-groups as follows: systemic symptoms group (n=530), respiratory symptoms 
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group (n=896), gastrointestinal symptoms group (n=249) and runners who failed 
the “neck check” (n=878). All runners (N=7035) were then followed on race day 
and information about each runner was obtained from a database of the race 
organizers. Data were obtained on the number of runners who did not start the 
race, and runners who started the race but did not finish the race. Data were also 
obtained from the medical stations on route and the medical tent at the finish line. 
All runners who were treated at a medical facility were considered to have a 
medical complication. 
 
The following outcome variables were then compared between the control group 
and the symptomatic group and sub-groups: 1) The period prevalence (%) of 
runners with symptoms of an acute illness in the 7-days prior to an endurance 
race, 2) the did-not-start (DNS) rate (% runners) in runners in different groups, 3) 
the did-not-finish (DNF) rate (% runners) in runners in different groups, and 4) the 




Phase 1: Review 
The review showed that there are very little data on the period prevalence of an 
acute illness in the few weeks prior to an endurance running race. It is however 
well established that endurance athletes (including distance runners) are at an 
increased risk to develop an upper respiratory tract (URT) illness during periods 
of high volume training (high intensity, long duration/ distance or high frequency) 
and the relationship between the “dose of exercise” and the risk to develop an 
URT illness follows a “J” shaped curve. In most studies there was reliance on 
self-reported symptoms using questionnaires and as such, URT illness were 
never diagnosed as being infective. Other causes for URT illness symptoms, 
such as allergies or asthma, should thus be investigated. 
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Specific risk factors for athletes for the development of an URT illness were 
identified and the influences that exercise has on various parameters in the 
immune system were reviewed. An acute illness can negatively affect an 
athlete’s exercise performance as well as have effects on various systems in the 
body. The systems most affected are the neurological system, cardiovascular 
system, musculoskeletal system, metabolic system and thermoregulation and the 
influences on these systems are discussed. Exercising with an acute illness is 
not without risk and the potential medical complications, including myocarditis 
and rhabdomyolysis, are reviewed. Possible strategies to prevent acute 
infections in distance runners are reviewed. 
 
Several guidelines in relation to the return-to-play guidelines for athletes with an 
acute illness were identified. The most common clinical tool that is used by 
clinicians to advise athletes on return-to-play (RTP) following acute illness is the 
“neck check”. There are however no published data validating the use of the 
“neck check” as a RTP guideline.   
 
Phase 2: Research study 
In the cohort of 7035 runners, 1138 runners (19.02%) experienced symptoms of 
an acute illness in the 7-day period prior to the race. The most common symptom 
experienced by the runners was a sore throat (34.5%), followed by a runny nose 
(29.9%), general tiredness (27.8%), a blocked nose (23.3%) and headaches 
(22.6%). When these symptoms experienced by the runners during the week 
prior to the race were grouped into clusters of symptoms, 530 runners (7.5%) 
experienced acute systemic symptoms, 896 runners (12.7%) experienced acute 
respiratory symptoms and 249 runners (3.5%) experienced acute gastrointestinal 
symptoms. In addition, 6157 runners (87.5%) passed the “neck check”, while 878 
runners (12.5%) failed the check. 
 
The did-not-start (DNS) rate for the symptomatic group was 10.8%, which was 
significantly higher than the DNS rate for the control group (asymptomatic 
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runners)(6.2%)(p<0.0001). In the sub-groups of symptomatic runners, the DNS 
rate for the runners with systemic symptoms was highest (14.7%) and this was 
significantly higher than the control group (p<0.0001). Runners who experienced 
gastrointestinal symptoms also had a high DNS rate of 12.1% (p=0.0003 vs. the 
control group), while runners who experienced respiratory symptoms had a DNS 
rate of 11.7% (p<0.0001 vs. the control group). Similarly, the DNS rate for the 
runners who failed the “neck check” was 12.2% (p<0.0001 vs. the control group). 
 
The DNF rate for the control group was 1.8%, which was similar to that of the 
symptomatic group (2.2%) (p=0.3778). Runners who experienced systemic 
symptoms in the 7 days prior to the race had the highest DNF rate (2.7%) 
(p=0.1954 vs. control), followed by the runners who experienced gastrointestinal 
symptoms during the 7 days prior to the race (2.3%) (p=0.16 vs. control) and 
runners who experienced respiratory symptoms (1.8%) (p=0.9571 vs. control). 
Runners in the failed “neck check” group had a DNF rate of 2.2% (p=0.4319 vs. 
control). There was also no statistically significant difference in the medical 
complication rates between the symptomatic group (0.34%) and the control 
group (0.22%) (p=0.4844). The MC rate of the runners who passed the “neck 
check” was 0.24% and the rate for the runners who failed the “neck check” was 
0.26% (p=0.9306 vs. control group). The runners who experienced systemic 
symptoms during the 7 days prior to the race had a MC rate of 0.44% (p=0.3782 




The results of this study showed that most the common illnesses amongst 
runners are acute respiratory conditions (URT illness), followed by 
gastrointestinal disorders and then dermatological conditions. The period 
prevalence of runners with an acute illness one week prior to an endurance race 
was 19.2% and this is novel data, as no studies could be found in our review 
which indicated the period prevalence of runners with an acute illness 7 days 
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prior to an endurance race. The most common symptom of acute illness was a 
sore throat (34.5%).  
 
A screening process and an educational intervention program resulted in a DNS 
rate that was significantly higher in the symptomatic group compared with the 
control groups, while the DNF and MC rates were similar between the two 
groups. This indicates that runners who reported symptoms of acute illness, and 
who were given educational information, had a significantly higher did-not-start 
(DNS) rate compared with control (no reported symptoms) runners. Runners who 
reported symptoms of acute illness, and who were given educational information 
but decided to start the race, had a similar did-not-finish (DNF) rate and medical 
complication (MC) rate compared to control runners. We suggest that the higher 
DNS rate in the symptomatic group was as a result of the educational information 
that was provided. We cautiously conclude that the educational information was 
effective in increasing the DNS rate in runners with more severe illness that could 
lead to a potential medical complication. It would also appear that those runners 
with pre-race symptoms who received the screening and educational information 
and then did start the race, despite a history of pre-race illness, did not have an 
increased risk. 
 
We also noticed that 12.5% of runners reported symptoms that would result in a 
failed “neck check” and this may place these runners at a particular high risk of 
developing medical complications during a race. Current clinical guidelines 
indicate that an athlete who experiences systemic symptoms (i.e. failing the 
“neck check”), should not be allowed to exercise due to the possibility to develop 
a medical complication. In our study we showed that in sub-groups with a 
potential higher risk for medical complications, the DNS rate was higher: 
systemic symptom group (14.7%), failed “neck check” group (12.2%), and 
gastrointestinal symptom group (12.1%). These data indicate that a screening 
process can identify runners with acute illness symptoms, and that an 
educational intervention can be applied resulting in an increased rate of not 
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starting a race. We cautiously conclude that a screening and educational 
program may reduce the risk of developing medical complications during an 
endurance race.  
 






























Introduction and scope of the thesis 
 
One of the most common clinical challenges a sport and exercise medicine 
physician encounters on a regular basis is whether an athlete is eligible to 
exercise or participate in a sports event while being acutely ill. This is a complex 
challenge, and a number of factors have to be considered: 
 What puts the athlete at risk to develop an illness? 
 How often does this occur in athletes? 
 Does an acute illness negatively affect exercise performance? 
 Are there any negative health consequences for the athlete if an incorrect 
decision is made? 
 Is the clinical approach the same for all acute illnesses? 
 Are there evidence-based guidelines to assist the clinician in making a 
correct clinical decision? 
 Are there any preventative strategies to reduce the risk of acute illness in 
athletes?  
 
This dissertation explores this area of sport and exercise medicine. In Chapter 2, 
a review of the existing literature that addresses these factors will be presented. 
The first section in this chapter will explore the epidemiology of acute pre-race 
illness, the relationship between exercise and pre-race illness, the risk factors for 
developing and acute upper respiratory tract (URT) illness in athletes, the 
relationship between exercise and the immune system, the common cause for 
acute illness in athletes and the effect of acute illness on the athlete’s exercise 
performance. The second part of Chapter 2 will address the clinical aspects of 
acute URT illness, the return-to-play guidelines for acutely ill athletes, possible 
medical complications when exercising with an acute illness, and the possible 
preventative strategies that can be implemented in an attempt to prevent acute 
illness in athletes. 
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In Chapter 3 the results of an original research study are presented that was 
designed to address the following research question: “Does a screening and 
educational intervention program for acute illness before a distance race 
influence runner behaviour and result in a lower rate of inability to finish a race 
and medical complications during the race?” The aim of this prospective cohort 
study in 7035 runners was to determine 1) the period prevalence of runners with 
symptoms of an acute illness one week prior to an endurance race [the 2012 
Two Oceans Race (21km and 56km)], 2) the period prevalence of runners who 
“fail” the “neck check” and would be advised not to participate in the race, 3) the 
incidence of runners with an acute illness, and who received educational 
information and guidelines, and who then not start the race, 4) the incidence of 
runners with an acute illness who chose to start the race, but do not finish the 
race, and 5) the incidence of runners with an acute illness who chose to start the 
race, but develop medical complications during the race. These data will provide 
some evidence if such a program makes racing with an acute illness safer for the 
athletes. To our knowledge, this is the first study where such an educational 
intervention program was utilized. 
 
Finally, in Chapter 4, the results from this dissertation will be summarized and 















Acute pre-race illness in distance runners: A review of 
the epidemiology, risk factors, aetiology, clinical 
presentation and diagnosis, effects on performance, 






Acute illness, specifically infective illness, is a significant health concern for the 
elite athlete, the novice athlete, as well as the “weekend warrior” athlete who 
enjoys keeping fit and participating in sport. Apart from preventing an athlete 
from participating in important training sessions, an acute illness can also cause 
a decline in exercise performance or prevent the athlete from taking part in a 
competitive event, particularly when the athlete prepared for this event over 
months or even years. However, and most importantly, an acute infective illness 
can also increase the risk of medical complications and even sudden cardiac 
death during exercise ((1), (2), (3), (4)). 
 
It has been documented that adults are affected, on average, by 1 to 6 episodes 
of an acute infection, mostly the “common cold”, per year. However, there is 
some evidence that elite athletes undergoing intense training may suffer from 
even more frequent episodes of acute infective illness (1).  In recent years, it has 
also been documented in a number of epidemiological studies, that the most 
common system affected by acute illness in athletes is the respiratory tract, 
followed by the gastrointestinal system and then the dermatological system ((1), 
(5), (6), (7)). In this dissertation, the main focus will be on acute illness affecting 
the respiratory tract. The main reasons for choosing this focus are 1) this is the 
most common system that is affected by acute illness in athletes, and 2) this is 
also the system where most research data are available. Where appropriate, 
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specific reference will be made to acute illness affecting other systems such as 
the gastrointestinal, cardiovascular, and musculoskeletal systems.  
 
When an athlete participates in a training session or competition while suffering 
from an acute illness, there are potential health consequences. These medical 
complications can include less serious and more serious life-threatening 
complications, or even sudden death (8). To date, sport and exercise medicine 
physicians and general practitioners have utilised a clinical guideline, known as 
the “neck check”, to determine if athletes with acute respiratory tract illness can 
participate safely in a training session or a competition (9). However, there is 
very little literature to support and validate this clinical guideline. The focus of this 
dissertation is on acute pre-race respiratory tract illness in distance runners. 
More specifically, the focus is on clinical guidelines to determine if runners can 
participate in an endurance event if they suffer from acute pre-race (7 days 
before the race) respiratory tract illness. 
 
The aim of this chapter is to review the following aspects of acute illness in 
athletes with specific reference to acute pre-race illness in distance runners: 1) 
epidemiology, 2) risk factors, 3) aetiology, 4) clinical presentation and diagnosis, 
4) effects on performance, 5) medical complications, 6) return-to-play guidelines, 
and 7) prevention.  
 
2.2. Methodology of data acquisition 
 
The principle method for data acquisition was in the form of a search of well-
known databases for medical literature (including PubMed, EBSCO, and 
Medline) as well as Google Scholar. Potential publications were identified using 
the following keywords: acute infections, running, distance running, marathon 
athletes, risk, neck check, exercise, and illness. No specific date limitations were 
set. The primary aim was to identify publications with high-level evidence (level I 
and II), but lower level evidence (level III and IV), studies were also considered. 
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Study designs were determined and categorized according to the Oxford levels 
of evidence (Table 2.1.)  
 
Table 2.1. Oxford levels of evidence (10) 
Level of evidence Study design 
Level 1  Systemic review of homogenous randomized 
control trial (RCT) 
 Individual RCT with narrow confidence level 
Level 2  Individual cohort study 
 Low quality RCT 
Level 3  Individual case-control studies 
 Non-consecutive cohort study 
Level 4  Case series 
Level 5  Expert opinions 
 




In one of the earliest studies conducted to determine the risk of illness in distance 
runners, it was documented that 28% and 32% of runners entering the 1982 and 
1983 Glasgow marathons respectively, did not start the race, and the main factor 
given for not starting the race was injury or illness (11). Since then, a number of 
epidemiological data suggested that endurance athletes are at increased risk for 
the development of URT illness during periods of intense training and in the 2 
week period after marathon-type events ((2), (12), (13), (14), (15)). It has also 
been reported that there is a 100-500% increase in the risk of developing an URT 
illness in the weeks following an ultra-endurance running event (16), and 30-50% 
of athletes participating in endurance events such as marathon running will 
develop symptoms of an URT illness (8). However, the focus of this thesis is on 
pre-race illness; therefore, the remainder of this review will focus on pre-race 
illness affecting mainly the URT. 
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2.3.2. Period prevalence of acute pre-race URT illness in distance runners 
 
To our knowledge, there are only a few studies that have been conducted to 
determine the relationship between upper respiratory tract (URT) illness prior to 
or after a distance running event. In one study the incidence of post-race URT 
illness was reported, and in two studies, the period prevalence of pre-and post-
race illness was studied. 
 
One of the first studies to report the relationship between a distance running 
event and the development of acute illness was a prospective cohort study 
conducted at the Two Oceans Ultra-marathon in Cape Town in 1982. In this 
prospective cohort study, the post-race period (14 days post-race) prevalence of 
symptoms of URT illness was reported in 150 randomly selected runners and 
compared to individually matched controls that did not run. Symptoms of URT 
illness occurred in 33.3% of runners in the 14-day post-race period, compared 
with 15.3% of controls that did not run. Furthermore, post-race symptoms were 
common in the athletes who achieved faster race times (17). However the 
epidemiology of pre-race illness was not investigated in this study. 
  
To our knowledge, the first study to examine the relationship between distance 
running and pre- and post-race illness was conducted at the 1987 Los Angeles 
Marathon (14). In this epidemiological study, runners reported episodes of URT 
illness for the 8-week period before and the 1-week period after a marathon race. 
Notably, 40% of the runners reported at least one period of URT illness during 
the 8-week period before the marathon. Furthermore, distance trained per week 
was identified as a possible risk factor to develop an URT illness after a 
marathon.  
 
In one other prospective cohort study the period prevalence of illness episodes 
were reported in the 3 weeks before and 3 weeks after the 2000 Stockholm 
Marathon (18). In this study of 1694 runners, 17% of runners reported an URT 
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illness in the 3-week period prior to the marathon. It should be noted that, 
although this was a random sample of all entrants, there was a significant 
dropout rate from the original cohort that was studied. Nevertheless, these data 
indicate that a significant percentage of runners experience pre-and post-race 
symptoms of acute URT illness. 
 
It should be noted that in all these studies self-reported symptoms of illness were 
documented. It had always been assumed that these symptoms of URT illness 
were as a result of an infection, possibly resulting from a depressed immune 
system. However, this diagnosis is subjective and non-scientific, as there is 
evidence that these symptoms are not necessarily as a result of an infection. 
Further studies are needed to determine the cause of these symptoms that can 
include allergies ((8), (16), (19), (20)), pollution ((8), (16), (21)), airway 




In summary, there are few studies in which the period prevalence of pre-race 
acute illness has been studied in distance runners. However, data from two 
studies indicate that this is a significant medical problem with 40% of runners 
reporting acute URT illness in an 8-week pre-race period, and 17% reported pre-
race URT illness in a 3-week pre-race period. It is also noted that in these 
studies, the acute pre-race illness was attributed to an infection, and this may not 
be valid. This will be explored in section 2.5 of this review.  
 
2.4. Risk factors for acute URT illness in distance runners 
 
Numerous risk factors for developing an acute URT illness have been identified.  
These can be broadly classified as either intrinsic (inherent to the athlete) or 
extrinsic (environmental and other factors). An in-depth review of these risk 
factors is beyond the scope of this dissertation, but the evidence that these 
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factors are associated with acute URT illness in athletes will now be briefly 
reviewed. 
 
2.4.1. Intrinsic risk factors 
 
2.4.1.1. Immune system depression 
 
There is an extensive body of literature describing the relationship between 
exercise and the immune system – known as exercise immunology  ((8),(12), 
(13), (16), (21)). A comprehensive review of this field is beyond the scope of this 
dissertation. However, there is strong evidence that changes in the immune 
system occur in response to acute bouts of exercise and prolonged training. 
Transient or more prolonged immune depression is also the basis of the 
pathophysiology and risk of acute illness in the exercising individual, including 
endurance athletes. Therefore, a brief overview and summary of the main 
changes in the immune system, as a result of participation in an acute exercise 
session or prolonged training, will now be presented. These changes in the 
immune system following exercise sessions or prolonged training are likely 
related to the other intrinsic and extrinsic risk factors, and these will also be 
reviewed briefly. 
 
Immune system depression and a single exercise session 
 
It has been well documented that there are changes in a variety of immune 
system component numbers and/ or functions following a single intensive 
exercise session. These changes include an increase in circulating neutrophils 
((8), (16), (21)), a decrease in the lymphocytes ((8), (21)), a decrease in 
neutrophil function (oxidative activity and phagocytic capacity) for 1-3 days after 
the exercise session ((8), (13), (21)), a reduction in natural killer (NK) cell 
numbers and cytotoxic activity ((8), (16), (21)) and a decrease in the salivary IgA 
concentrations ((8), (12), (13), (21)).  
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There is an increase in the neutrophil: lymphocyte ratio (used as a predictor of 
stress to the immune system) for most of the following day after a heavy exercise 
session ((15), (21)). There is also an increase in pro- and anti-inflammatory 
cytokines (including interleukin-6 and interleukin-10) ((8), (13), (21)), an elevated 
concentration of T-helper 2 lymphocytes (8), and a shift towards type 2 T-cell 
dominance ((8), (16), (22), (23)). 
 
A higher plasma concentration of several hormones (such as epinephrine, 
cortisol, growth hormone and prolactin) occurs after a heavy exercise session 
and acute phase proteins such as C-reactive protein (CRP) is induced ((16), 
(21)). A 20% reduction in plasma glutamine concentration may occur (21). 
 
There is conflicting evidence regarding T-cell function. In some studies it has 
been documented that T-cell function declines after an intense exercise session 
((13), (15), (21)), while other data indicate that the T-cell function does not 
change ((8), (12)). 
 
A single bout of exercise thus results in changes in various immune parameters. 
These changes may last for 3-72 hours. This period is known as the “open 
window” period phenomenon during which time these changes in the immune 
system may predispose an athlete to viral and bacterial infections ((3), (8), (12), 
(13)). 
 
Despite evidence that certain immunologic parameters change after an acute 
intense or prolonged exercise session, there is a lack of evidence to indicate that 
there is a direct link between the altered immune parameters and an increased 
incidence for URT illness symptoms post-exercise ((8), (9), (16), (21)). 
 
Immune system depression and prolonged training 
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It has been documented that post-exercise immune dysfunction is most 
pronounced when the exercise session is more than 90 min long and the 
intensity is 55-75% of maximum oxygen uptake (V02Max) (16), while other data 
indicate that a session longer than 60 min at an intensity > 80% of maximum 
ability cause a depression in the immune system (8). It has also been shown that 
overtraining (daily training over a long period of time) leads to immune 
suppression which may render the athlete susceptible to an URT illness ((1), 
(24)). 
 
Prolonged exercise (2.5 to 3 hours of intensive running) is associated with an 
increase in neutrophils (13), a decrease in lymphocytes ((13), (16)), an increase 
in neutrophil phagocytosis (13), and a decrease in natural killer cell activity 
(NKCA) ((13), (16)) that can last for 6 hours. The decrease in NKCA appears to 
be related to the decrease in the number of circulating NK-cells after prolonged 
training ((13), (16)). The neutrophil oxidative burst activity however show a small 
decrease ((12), (13)) and there are some evidence that plasma cortisol and 
epinephrine inhibit mitogen-induced lymphocyte proliferation (13). 
  
T-cell function decrease for 3 hours after a 2.5 hour intensive running session 
(13) and salivary IgA decreases after 2 to 3 hours of intensive endurance 
exercise ((13), (21)). Following prolonged, strenuous exercise, the production of 
immunoglobulins by B lymphocytes is inhibited (16).  
 
The mucosal immune system and the innate non-specific immune system 
together form the body’s first line of defence against pathogenic organisms (8), 
as secretory IgA inhibits pathogens’ attachment to the upper respiratory tract and 
thus prevent the entry of the pathogens into the body (12). It has been 
documented that salivary IgA is decreased after a prolonged or high intensity 
exercise session, increasing the athlete’s risk to develop URT illness symptoms 
(23). A series of studies have also been conducted to document the immune 
responses of elite swimmers during training (20). These data show that 
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swimmers with a lower pre-season salivary IgA and/or lower pre-exercise 
salivary IgA concentrations had an increased risk to develop an URT illness 
during a 7-month training period, compared with controls. 
 
Therefore, these data support the hypothesis that regular high-intensity or 
prolonged exercise bouts increase the risk of an URT illness, as prolonged 
training may result in chronically impaired immune function.  
 
Summary: Immune system depression 
 
It has been well documented that various components of the immune system are 
altered by acute bouts of prolonged, continuous exercise (Table 2.2.) There is 
however little evidence to link the specific exercise-induced changes to an 



















Table 2.2. Changes in immune system components following acute bouts 
of prolonged continuous exercise 
 
Component / component function Perturbation 
Lymphocyte count Decrease  
Neutrophil count Increase 
Neutrophil: lymphocyte ratio Increase  
Oxidative burst of neutrophils Decrease  
Neutrophil chemotaxis and 
phagocytosis 
Decrease  
NK cell count Decrease  
NKCA Decrease 
CRP Induced 
Salivary IgA Decrease  
Immune response Shift towards T2 immune response 
T-cell function No consensus 
B-cell function Unchanged 
Lymphocyte proliferation Decrease  
Monocyte count Increase 
Glutamine concentration Decreased 
 
NK (Natural killer) 
NKCA (Natural killer cell activity) 
CRP (C-reactive protein)   
 
 
2.4.1.2. A history of a recent URT illness 
 
There is some evidence that a history of a recent acute illness may predispose 
an athlete to an increased risk of illness. In one prospective cohort study 
conducted during the Stockholm Marathon, 33% of athletes who experienced an 
URT illness in the 3-week period prior to the race developed an URT illness in 
the 3-week period after the race (18). This was significantly greater than the 16% 
of athletes who did not have an URT illness prior to the marathon. These data 
suggest that strenuous exercise too soon after an acute illness may be a risk 
factor to develop a subsequent illness. However, these data have not been linked 
to specific changes in the immune function (section 2.4.1.1.) in athletes who 
return to exercise training following acute illness. As this is also the only study 
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relating previous acute illness to increased risk of illness, this area requires 
further study. 
 
2.4.1.3. Female gender 
 
There is some evidence to suggest that female athletes are at higher risk of an 
acute illness. In one prospective cohort study, 210 endurance athletes (63 
females and 147 males) completed a self-report health questionnaire on a daily 
basis for 16 weeks (25). It was documented that the proportion of participants 
who experienced one or more periods of URT illness symptoms, was 40% in 
males and 52% in females. The mean duration of URT illness symptoms was 
also longer in female athletes (15.5 days) compared to the males (11.6 days) 
(p=0.024), and the number of URT illness symptoms days were higher in females 
(6.8 days) than in males (4.7 days) (p=0.016). 
 
In the International Olympic Committee’s injury and illness surveillance study 
conducted at the 2012 Winter Youth Olympic Games held in Innsbruck (N=1021), 
it was reported that the incidence of acute illness was 84.2 illnesses per 1000 
athletes (6). With regard to gender, 6% of male athletes and 11% of female 
athletes suffered from an illness (p=0.003). A similar finding was documented 
during the 2012 Summer Olympic Games held in London, where a daily injury 
and illness occurrence was recorded (5). The illness incidence was 71.7 illnesses 
per 1000 athletes and females had a higher incidence if illness compared with 
male athletes (8.6% vs. 5.3%). Therefore, a number of studies indicate that 
female gender is a risk factor for acute illness in athletes, but this requires further 
investigation. 
 
2.4.1.4. Increased body mass index (BMI) 
 
There is some evidence that an increased BMI is associated with increased risk 
of acute illness in athletes. In one prospective cohort study, illness patterns were 
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studied in 530 male and female runners who completed a monthly log for 12 
months. The results of this study show that a BMI > than the 75th percentile was 
associated with an increased risk to develop an URT illness (26). Therefore, 
there are data to suggest that an increased BMI increases a runner’s risk to 
develop an URT illness, but this needs to be verified by more studies. 
 
2.4.2. Extrinsic risk factors 
 
2.4.2.1. Increased training load 
 
It has been documented that sedentary individuals have a higher incidence of 
symptoms of URT illness compared with individuals who engage in regular 
moderate exercise (50-70% of maximum ability, 30-60 minutes per session, 3-5 
sessions per week) (8). It has also been documented that regular intense and 
prolonged exercise bouts may increase an individual’s risk to develop and URT 
illness, as such training may result in a chronic depression of the immune system 
(section 2.4.1.1.). 
 
The relationship between the training load (“dose”) of exercise and the risk of 
URT illness symptoms is commonly reported as a “J-shaped” curve ((2), (3), (8), 
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Figure 2.1. The “J-shaped” model depicting the relationship between 
varying amounts of exercise and the risk of developing URT symptoms 
 
Data from a number of well-conducted studies support this “J-shaped” model for 
the relationship between exercise and the susceptibility to acute URT illness. It 
has been documented that in one randomized control trial, 36 woman walked 
briskly for 45 min, 5 days per week for a 15-week period (15). The results of the 
study showed that active woman experienced symptoms of URT illness on 5.1 
days during this 15-week period, compared to the sedentary control group who 
experienced symptoms of URT illness on 10.8 days (p<0.05). It has also been 
documented that in another randomized trial, elderly woman were monitored over 
a 12-week period (15). Women who walked 40 min, five times per week, had a 
12-week incidence of URT illness of 21% compared with 50% for a sedentary 
control group (15). 
 
In an observational study of 547 healthy adults (49% women) aged 20-70 years, 
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evaluations) (23). Three 24-hour physical activity recalls per evaluation were 
obtained and averaged to quantify total moderate-vigorous activity (> or =3.0 
metabolic equivalents [MET]). Associations between URT illness and physical 
activity levels were estimated using incidence rate ratios (IRR). The results 
indicated a 29% reduction in the incidence rate of URT illness symptoms in adult 
men and women who engaged in moderate physical activity of at least 6-7 
metabolic equivalents (METS) per hour per day, when compared to individuals 
who were less active.  
 
In summary, data from well-conducted studies (level 1 and 2) support the 
hypothesis that sedentary individuals have a higher incidence of URT illness 
symptoms compared to people who exercise at a moderate intensity or duration. 
 
However, in runners training more than 97 kilometres (km) per week, there was a 
two-fold increased risk for developing an URT illness compared to runners who 
trained less than 32 km/week (14). These data suggest that strenuous training 
increases the risk for developing an URT illness. In one prospective cohort study, 
illness patterns were studied in a cohort of 530 male and female runners who 
completed a monthly log for 12 months (26). It was shown that runners who 
exceeded 777-1385 km (486-866 miles) during the 12-month period had a 
significantly higher risk of developing URT illness symptoms. Epidemiological 
data from studies on South African ultra-marathon runners also indicate that 
“heavy” acute or chronic exercise is associated with an increased risk of URT 
illnesses (15). 
 
However, it is very important to note that the “J-shaped model” is mostly based 
on studies that only examined self-reported symptoms that are associated with 
URT illness and not clinically diagnosed infections with a specific pathogen. This 
has led to some researches questioning the validity of this model (23).  
 
 31 
In only one prospective cohort study there are data to support the “J”-shape 
hypothesis for documented URT infection (19). In this study, 32 elite athletes, 31 
recreational athletes and 20 sedentary individuals were followed over a 5-month 
period. Individuals who reported symptoms of URT illness were tested with throat 
and nasopharyngeal swabs for the presence of viral and bacterial pathogens. 
Nine sedentary, 7 recreational and 21 elite athletes developed an URT infection 
(37 URT infections in 28 subjects). Although actual pathogens were only found in 
less than 30% of all the cases, these data support the J-shaped hypothesis.  
However, these data also indicate that both infectious and non-infectious (allergic 
reactions, airway hypersensitivity and other causes) causes for URT illness 
should be considered when an athlete presents with symptoms of URT illness. 
 
In the studies mentioned above, there was no clear distinction between the 
different components that define an “increased” or “heavy” training load. The 
main components determining training load are duration of exercise, frequency of 
training, and intensity of exercise. In a number of studies, duration and frequency 
are frequently combined as training volume (daily, weekly, or annual). The 
specific relationship between these components and risk of URT illness in 
runners will now be briefly explored. It should be noted however that there are 
very few studies where the relationship between URT illness and these 
components of training load have been reported. 
 
Training volume and risk of URT illness 
 
In one epidemiological study, it was documented that athletes who trained more 
than 96km/week for the Los Angeles Marathon, had a > 2 fold increased risk of 
developing an URT illness when compared to athletes who trained less than 
32km/week (14). In a prospective cohort study, it was shown that an annual 
training distance > 777km (486 miles) was a risk factor for developing an URT 
illness (26). It has also been documented that training volume > 65km/week was 
a risk factor for developing an URT illness (8). The mechanism of this appears 
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may be related to a reduction in immune system function as a result of prolonged 
training.  
 
Intensity of exercise and risk of URT illness  
 
To our knowledge, there are no epidemiological data relating training at 
increased intensity to an increased risk of acute illness – including URT illness. 
However, there are data indicating that immune dysfunction is most pronounced 
in athletes who train at a higher exercise intensity (50-75% of maximal oxygen 
uptake) (16). Other data indicate that an exercise intensity level greater than 80% 
of maximum ability is associated with a depressed immune system (8). In 
summary, there is some evidence that increased training intensity is associated 
with a reduction in immune function that may increase the risk of developing URT 
illness in distance runners. 
 
2.4.2.2. Nutritional factors 
 
The relationship between nutritional factors and increased risk of URT illness in 
endurance athletes has also been explored. In general, immune cells require an 
adequate amount of glucose, protein, water and electrolytes to maintain normal 
function (21). Therefore, a well-balanced diet is important for immune function. A 
detailed exploration of the relationship between multiple nutritional factors and 
the immune system is beyond the scope of this dissertation. However, in a 
review of 66 placebo-controlled and/or crossover trials, it was concluded that a 
poor nutrition state affects almost all aspects of the immune system (21). More 
specifically, an unbalanced diet (a high carbohydrate (CHO) intake at the 
expense of protein), training in a dehydrated state, and the excessive use of 




In addition, glucose is considered to be an important fuel substrate for various 
immune cells, including macrophages, lymphocytes and neutrophils. There is 
some evidence that frequent ingestion of a ≥ 6% CHO solution (1 litre per/hour) 
during prolonged or high intensity exercise maintains blood glucose levels, which 
lead to an attenuated post-exercise cortisol level, resulting in a less suppressed 
immune function. The ingestion of the CHO may also attenuate exercise-induced 
increases in the total leucocyte count and/or leucocyte subsets such as 
monocytes and neutrophils, and cytokine changes, which usually leads to a 
decreased immune function (21).   
 
Finally, it has been documented that the immune function is suppressed during 
periods of low calorie intake and weight loss (15), and data show that inadequate 
nutrition and exercising without food intake may contribute to an impaired 
immunity, which makes the individual more susceptible to infection (21). 
 
2.4.2.3. Other extrinsic risk factors 
 
Inadequate recovery from training 
 
It has been documented that a single bout of strenuous exercise (a prolonged 
session at high intensity) is followed by a period of temporary immune 
suppression ((2), (8), (12), (16), (21)). As mentioned already, this has been 
termed the “open window” period ((2), (8), (12), (21)), and during this post-
exercise period, a runner may be more susceptible to infections. If sufficient 
resting periods between strenuous exercise sessions are not allowed, the athlete 
is at an increased risk to develop an URT illness, as the immune function has 
insufficient time to recover from the perturbations caused by the strenuous 
exercise session ((2), (3), (8)). Therefore, inadequate recovery after strenuous 
exercise session may be an important risk factor for acute illness. Increased risk 
of illness has also been related to fatigue (2), and overtraining ((1), (2), (8)). 
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Poor sleep and increased psychological stress 
 
There is evidence that other extrinsic factors such as alterations in normal sleep 
patterns and psychological stress can increase the risk of acute illness ((15), 
(21)). A summary of risk factors for developing an URT illness is depicted in 
Table 2.3. 
 
Table 2.3. Risk factors for developing an URT illness 
 Risk factor Variable 
Intrinsic Immune system Depression of a number of immune system 
components  
 Medical history History of recent URT illness 
 Gender Female 
 BMI BMI > 75th percentile  
Extrinsic Training volume >97km / week 
>65km / week 
 Training intensity >80% of maximum ability 
 Nutrition  Inadequate CHO intake  
Inadequate calorie intake 
Exercise in dehydrated state 
Exercise without food intake 
 Other extrinsic 
factors 







2.5 Aetiology of acute URT illness in athletes 
 
An URT illness can be defined as clinical symptoms and signs affecting the 
upper respiratory tract as a result of a either infective or non-infective cause. An 
URT infection can be defined as an acute illness affecting the nasopharynx, 
caused by microbial agents, and resulting in local and sometimes systemic 
symptoms.  A detailed review of the aetiology, microbiology and pathophysiology 
 35 
of acute URT illness is beyond the scope of this dissertation. However, it is well 
documented that infective URT illness is most commonly caused by viruses (8), 
but can also be caused by bacteria and fungi. There are more than 200 different 
viruses causing colds, and the rhinoviruses and coronaviruses are the pathogens 
in 25-60% of the time (12). The most common viruses causing various URT and 
related infections are depicted in Table 2.4. 
 
Table 2.4. Most common viral causes for URT and related infections 
Disease Organism 




Influenza Influenza (ABC) 
URT infection Adenovirus 
Parainfluenza 
Coxsackie A 
Respiratory syncytial virus 
Lower respiratory tract infection Adenovirus 
Respiratory syncytial virus 
Infectious mononucleosis Ebstein-Barr virus 
 
Rhinovirus infections usually occur during spring and autumn, while infections 
are commonly caused by the coronavirus during winter time (12). The most 
common virus involved in URT infection is the rhinovirus (19). A viral infection 
usually lasts for 3 to 14 days.  
 
As mentioned, URT illness symptoms are not always due to an URT infection 
caused by the common viruses or bacteria. In one prospective study performed 
on elite athletes, it was shown that pathogens were identified in less than 30% of 
athletes who reported symptoms of an URT illness (19). In 2 other studies, 
cultures were taken from athletes who complained about URT illness symptoms 
after an ultra-marathon race. The cultures showed no growth (8). Therefore, 
other systemic infectious and non-infectious conditions should be considered 
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when an athlete presents with symptoms of an “URT infection” ((27), (28)). These 
causes are summarised in Table 2.5. 
 
Table 2.5. Infectious and non-infectious causes of URT illness symptoms 
Sub-group  Condition 
Systemic infectious 
conditions 
 Infectious mononucleosis 
 Tuberculosis 
 Systemic infections (rubella, chickenpox etc.) 
 Ludwig’s angina 
Non-infectious conditions  Allergic rhinitis 
 Asthma 
 Wegener’s granulomatosis (type of vasculitis) 
  
 Gastro-oesophageal reflux disease 
 Obstructive sleep apnoea 
 Acute thyroiditis 
 
Of these conditions, allergic rhinitis is one of the most common conditions that 
can mimic an URT infection. It is important to note that by taking a thorough 
history, and conducting a clinical examination, allergic rhinitis can be 
differentiated from an URT infection. 
 
In summary, URT illness symptoms can be due to infectious and non-infectious 
causes. Viruses most commonly cause infectious URT illnesses and the most 
commonly implicated virus is the rhinovirus, followed by the coronavirus. Non-
infectious URT illness symptoms are most commonly caused by an allergic 
rhinitis, and taking a thorough history and performing a good physical 
examination can usually distinguish between an URT infection and allergic 








2.6. Clinical presentation and diagnosis of acute URT illness in 
athletes 
 
2.6.1. Symptoms and signs of an URT illness 
 
Symptoms of an URT infection can be divided into localised and systemic 
symptoms. Localised symptoms will include a blocked or runny nose, sore or 
scratchy throat, sinus congestion and sneezing. Systemic symptoms include 
fever, malaise, myalgia (muscle pain), arthralgia (joint pain), lymphadenopathy, 
coughing and an increased resting heart rate. It is important to differentiate 
between localised and systemic symptoms, as these symptoms form the basis of 
the “neck check” guideline that has been proposed and is utilised by physicians 
to advise athletes with symptoms of an acute URT illness on participation in sport 
((1), (2), (9)). Specifically, these clinical guidelines suggest that athletes who 
have systemic symptoms are not eligible to exercise. 
 
A thorough clinical examination is important as more serious conditions can 
mimic an URT illness. Signs on clinical examination can also be divided into 
localised and systemic physical signs. Local signs include tenderness over the 
sinuses, throat erythema and nasal mucosa engorgement while systemic signs 
include lymphadenopathy, tachycardia, fever, and rhonchi or crepitations in the 
lungs. 
 
It is important to note that there are other infective conditions that can mimic a 
localized viral URT infection. Infectious mononucleosis (IM) is one of these 
conditions and can present in the same manner as pharyngitis (sore throat, 
lymphadenopathy and fever). An enlarged spleen (which can be difficult to 
palpate) might be the only clinical indication that the athlete has IM. This has 
consequences for the return to play guidelines (as discussed in Section 2.9). 
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Myocarditis is another condition that can initially present with similar clinical 
characteristics to an URT illness (fatigue, malaise, fever, myalgia and 
palpitations). A tachycardia out of proportion to the degree of pyrexia, a muffled 
1st heart sound and apical systolic murmur are clinical signs that may direct the 
clinician towards a clinical suspicion of myocarditis (8). 
 
2.6.2. Special investigations 
 
Special investigations are very seldom performed in an uncomplicated URT 
illness, as the cause is usually a virus. Viral cultures and polymerase chain 
reaction (PCR) tests are only indicated in patients for whom specific anti-viral 
therapy is recommended. A pharyngeal swab for rapid antigen detection of group 
A beta-haemolytic streptococci can be performed, and this test is 90% sensitive 
and 95% specific in adults. However, an antistreptolysin O test is generally not 
helpful in the acute illness and is usually only detected several days after an 
infection began (27). 
 
Special investigations are also indicated when other viral conditions mimicking an 
uncomplicated URT illness are suspected. One such condition is infectious 
mononucleosis (IM). When IM is suspected, a full blood count (FBC) can be 
performed that may show an elevated white cell count (WCC) with atypical 
lymphocytes accounting for up to 30% of the differential WCC. The presence of 
heterophile antibodies (Monospot test) may confirm the diagnosis in 85-90% of 
cases. The Epstein-Barr virus antibodies are both specific and sensitive for 
Epstein-Barr infection and the capsid antigen IgM is usually positive. An 
ultrasound of the abdomen may show splenomegaly (8). Allergic rhinitis is 
another condition that may cause symptoms of URT illness, and an elevated IgE 
will direct the clinician towards an allergy related URT illness.  
 
Myocarditis is an important complication that may be associated with acute URT 
illness. If myocarditis is suspected, a Troponin T and Troponin I blood test should 
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be performed, as well as an ECG and echocardiogram (8). Viral myocarditis and 
myopericarditis are discussed in section 2.8.1 and section 2.8.2. 
 
When a Coxsackie virus is suspected, Coxsackie antibodies can be tested. The 
results will be given as titres for several of the Coxsackie viruses and, if 
indicated, the IgM for a specific Coxsackie virus can then be requested. 
 
In summary, a number of special investigations can be requested to confirm the 
diagnosis of specific conditions that can cause URT illness (Table 2.6.) 
 
Table 2.6. Indications for special investigations in URT illnesses 
 
Special investigation Indication 
Viral cultures and PCR Specific anti-viral therapy is recommended  
Pharyngeal swab – 
rapid antigen detection 
Group A β-haemolytic streptococci suspected 
FBC 
Monospot test 
Ultrasound of abdomen 





Viral myocarditis suspected  
Coxsackie anti-bodies Coxsackie virus suspected 
Serum IgE Allergic rhinitis suspected 
 
 




Infections, including URT infections, and / or bed rest (which is part of the 
treatment of most infections), can influence several organ systems and 
physiological parameters in the body. Acute febrile infections are associated with 
circulatory deregulation, muscle wasting, impaired motor coordination (3), a 
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decrease in muscle strength and endurance, an inability for the body to regulate 
body temperature, a reduction in exercise tolerance, and an increase fatigability 
(2). This can have consequences for the athlete’s exercise performance. It has 
been documented that even a minor infections can cause a decrease in exercise 
performance and reduce the ability to sustain high intensity or prolonged training 
(16). 
 
Many athletes regularly experience a sudden and unexplained decrease in 
exercise performance. Physiological fatigue should be excluded first and this 
includes overreaching, inadequate sleep, dietary causes, jet lag, pregnancy, and 
depleted iron stores. However, once it has been established that the athlete may 
suffer from a pathological fatigue and no obvious pathology can be found in any 
of the systems, a recent viral infection should be suspected (15). Infections that 
are subclinical in the non-athletic population may affect maximum exercise 
performance in athletes (29). Furthermore, athletes often complain about a 
decrease in exercise performance once in the recovery period following an URT 
infection. It has been documented that this decrease in exercise performance 
after full clinical recovery from an URT illness can last for 2 to 4 days (8). 
 
In four different case reports, athletes complained of loss of stamina, inability to 
maintain their normal training load, tiredness and a decrease in exercise 
performance (29). Laboratory results indicated that 2 of the athletes had recent 
Coxsackie infections, one had infectious mononucleosis and the 4th athlete had 
recent infectious mononucleosis. It is worth taking note that 2 of these athletes 
had only minor symptoms of URT infections, and the other 2 athletes had no 
prodromal symptoms. 
  
Apart from the general effects of a febrile illness on exercise performance, a 
number of specific organ systems can be affected by an acute illness. The effect 
of acute illness on these systems, and the relationship to reduced exercise 




2.7.2. Neurological system 
 
A febrile infective illness can affect the nervous system and this can lead to an 
impairment of coordination. In one study, 14 participants with influenza or 
echovirus infection, all suffering from myalgia, and 9 participants with mumps, in 
whom this symptom was lacking, were investigated with single-fibre 
electromyography (EMG) in the acute phase and during convalescence to reveal 
a possible disturbance in neuromuscular transmission (3). The results showed 
that both groups had abnormal neuromuscular transmission characteristics in the 
acute phase. This study demonstrates that acute febrile infections may lead to 
reduced neuromuscular transmission in the motor-endplate during the early 
phase.  
 
In another prototype experimental viral infection, isometric muscular strength and 
endurance of 10 male participants was measured four times per day for 15 
consecutive days (3). Eight experimental participants were inoculated with the 
sandfly fever virus and two double-blind controls were given sterile saline on the 
seventh day. The muscular performances of the control participants remained 
constant throughout, whilst a decrease in muscular strength and endurance 
speed, and a decrease in coordination in the performance of motor skills at 
submaximal force was observed in the inoculated group (3). Although no data 
are available to link these changes causally to exercise performance, altered 
neuromuscular control may increase the risk of ankle injuries in certain sports (3).  
 
2.7.3. Musculoskeletal system 
 
There is evidence that abnormalities of skeletal muscles occur in patients with 
viral infections (30). Mitochondrial abnormalities have been reported during an 
infectious episode (12), a reduction in muscle enzyme activity (glyceraldehyde 
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phosphate, lactate dehydrogenase, cytochrome oxidase and citrate synthetase) 
has been documented (1), and it has been shown that infections cause a 
decrease in the protein content of the skeletal muscle, leading to muscle wasting 
(3). The decline in muscle strength and endurance from the athlete’s baseline is 
correlated to the muscle protein loss caused by the infection (3), but it should 
also be noted that fever per se cause a decrease in muscle strength (1). It has 
been documented that both isometric and isotonic muscle strength decreased by 
30% on the first day of fever in an experimental sandfly fever (3). Although 
muscle biopsies showed no significant muscle protein degradation at that stage, 
the magnitude of the impairment significantly correlated with the participant’s 
ratings of subjective symptoms, including myalgia.  
 
Following a flu-like illness with fever that lasted about 36 hours, it may take as 
long as 2 weeks to replenish the accumulated muscle protein losses. This period 
is much longer in more severe infections, such as malaria (3).  
 
In summary, there is evidence that infection leads to a decrease in muscle 
protein content (which correlates to a decline in muscle strength and endurance), 
a reduction in muscle enzyme activity and mitochondrial abnormalities. It might 
take up to 2 weeks for the muscle protein to be replenished. Fever also causes a 
decrease in muscle strength. Therefore, it appears that a febrile illness negatively 
influences the ability to perform muscle work (3), and this may explain the 
decrease in exercise performance experienced by athletes after an URT infection 
(30).  
 
2.7.4. Cardiovascular system 
 
The normal physiology of the cardiovascular system, in response to an acute 
exercise bout, can be affected during acute febrile illness. It has been 
documented that fever reduces stroke volume and hence cardiac output, which 
correlates significantly with the severity of the fever (1). At the same time, fever 
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increase oxygen consumption and heart rate:  for every 1°C the body 
temperature rise above 37°C, there is a 13% increase in oxygen consumption, 
and for every 1.5°C increase in body temperature, the heart rate increase by 2.44 
beats per minute (1).  
 
It has been documented that during an infection, which requires bed rest, the 
aerobic exercise capacity (as determined from the heart rate response during 
submaximal exercise) can decrease by as much as 25% (3). This response has 
been attributed to the negative influence that an infection can have on the blood 
volume, total haemoglobin, myocardial function and peripheral factors i.e. the 
changes in the skeletal muscles caused by the infection (see section 2.7.3) (3). 
Of note, there are data indicating that low intensity physical activity during an 
infection, such as getting out of the bed every half-hour during waking hours, 
resulted in a smaller blood volume reduction and a smaller decrease in aerobic 
capacity compared to conventional bed rest (3).  
 
In one case study, data in an elite athlete engaged in a longitudinal program of 
physiological assessment, was reported (31). In this study, the athlete suffered a 
loss of performance as a result of a viral infection. During a prolonged 
submaximal exercise test in the post-viral period, there was a pronounced 
increased in the heart rate and perceived exertion ratings that led to the earlier 
termination of the test. The increased heart rate also influenced the graded 
exercise test and the cyclist could only complete 4 of the 6 stages. This is 
anecdotal evidence and further studies are required in this field.  
 
In summary, there is some evidence to indicate that a febrile illness decreases 
the blood volume, total haemoglobin, stroke volume and cardiac output, and 
increases the oxygen consumption. These changes can lead to as much as a 
25% reduction in endurance capacity. Some evidence exists to indicate that an 





It is well established that a febrile illness affects the body’s ability to regulate 
body temperature (2). As a result, this can increase fluid losses, which may put 
the athlete at a greater risk for dehydration and heat stroke (2). 
 
2.7.6. Respiratory system 
 
There is some conflicting evidence on the effect that an URT illness might have 
on the pulmonary system during periods of exertion. In one study the impact of a 
rhinovirus-caused URT infection on resting pulmonary function, submaximal 
exercise response, and maximal exercise functional capacity, was determined 
(32). The study consisted of 55 participants who were divided into a control group 
(N=10) and experimental group (N=45). All participants completed a baseline 
pulmonary function test and a graded exercise test to volitional fatigue after 
which the experimental group’s participants were inoculated with rhinovirus-16 on 
2 consecutive days. The day following the second inoculation, post-inoculation 
pulmonary function and graded exercise tests were performed on both groups. It 
was shown that, during the graded exercise test, there was no significant 
differences (p<0.05) in the physiological response measured at the 2, 5, and 8 
minute periods between the running trials for both the experimental group and 
control group. There was also no significant difference in the maximal exercise 
performance between the two groups. It thus appears that the physiological 
responses to pulmonary function testing at submaximal and maximal exercise 
are not altered by an URT infection. 
 
It has been documented that 3 studies were conducted on the effect of an URT 
illness on the pulmonary function of participants at rest (1). An impairment of 
peak expiratory flow rate, forced vital capacity, forced expiratory volume in 1 
second, and maximal mid-expiratory flow rate, measured at 50% of vital capacity, 
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was documented, but changes in the maximal expiratory flow rate measured at 
75% of vital capacity were not significant. 
 
It has also been documented that a study on respiratory muscle strength in 12 
participants who developed an URT illness showed that maximum static 
respiratory mouth pressures was significantly reduced during the infection (1). 
The greatest reduction was documented between the 3rd and 7th day of illness 
and returned to normal by day 14. The authors concluded that weakness of the 
inspiratory muscles might contribute to breathlessness of athletes during exertion 
whilst having an URT illness. Exercising during an on-going URT infection may 
cause bronchial hyperactivity (3). 
 
In conclusion, there are some evidence that an URT illness has a negative effect 
on the peak expiratory flow rate, forced vital capacity, forced expiratory volume in 
1 second, and maximal mid-expiratory flow rate, measured at 50% of vital 
capacity. These studies were however performed on participants at rest and 
studies performed on exercising participants showed that the pulmonary system 
is not affected by an URT illness during exertion, except that athletes might 
develop bronchial hyperactivity. More studies on exercising individuals with an 
URT illness are required in this field. 
 
2.7.7. Immune and metabolic responses 
 
Acute infections can also influence the normal physiological metabolic response 
to exercise. An acute infection activates macrophages and monocytes of the 
immune system. These cells release cytokines, which trigger an acute phase 
response (3). This non-specific cytokine-mediated response causes a shift in the 
metabolism in order to mobilise nutrients from the body tissues, predominantly 
amino acids from muscle tissues, to satisfy the increased nutritional needs of the 
activated immune system and to provide substrates for the accelerated energy 
production during fever (3). A feature of the acute phase reaction is thus the 
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induction of a generalized catabolism of muscle protein, as cytokines mediate the 
release of amino acids from the muscles and increased uptake of amino acids in 
the liver and other organs. As long as 2 weeks is required for the accumulated 
muscle protein losses to be replenished (3). 
 
Hormones that regulate carbohydrate (CHO) metabolism are intimately involved 
in the host defence response to infectious illnesses. A viral illness results in 
hyper-insulinaemia and a decrease in carbohydrate tolerance. This is possibly 
due to elevated levels of hormones antagonistic to insulin. These include 
glucagon, cortisol and growth hormone. The combined effects of the hormones 
cause a decrease in glucose storage, which can result in a depletion of tissue 
CHO during an illness. When an individual then exercise whilst being ill, 
hypoglycaemia can develop, as glucose in the blood will be oxidised at an 
accelerated level and less liver glycogen will be available to mobilise (31). The 
elevated insulin levels during an infection and fever also generally reduce the 
mobilisation of fatty acids from the fat stores (3), and the resting levels of serum 
fatty acids are known to be lowered in severe acute viral infections (31). 
 
In a case study on a 24 year old male elite cyclist who suffered a decrease in 
exercise performance after a viral illness, repeated measures indicated that the 
oxygen uptake equivalent to the onset of blood lactate accumulation of 4mmol 
per litre decreased by 17% following the viral illness, then slowly recovered (31). 
It was also indicated that, during prolonged exercise at 70% of VO2max, the 
proportion of energy derived from CHO metabolism increased, and an inability to 
maintain euglycaemia was observed (blood glucose decreased after 60 min of 
exercise). The blood lactate values were also significantly higher at all stages 
during a graded exercise test after the infection compared to tests before the 
infection. The authors was of the opinion that this could be either due to an 
accelerated flux through glycolysis, or a decrease in the rate of entry of pyruvate 
for mitochondrial oxidation. Although there is insufficient evidence in this case 
study, the increased blood lactate levels could have resulted from an abnormal 
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oxidative capacity of the muscles due to the viral infection, thereby requiring a 
greater contribution from anaerobic glycolysis to maintain the rate of adenosine 
triphosphate (ATP) production (31). 
 
It has been documented that a study was performed to determine the effect of 
viral and mycoplasma infections on the ultrastructure and enzyme activities in 
human skeletal muscle (1). For this, muscle biopsies were obtained from patients 
recovering from recent viral illnesses. The results of this study show that there 
was a significant reduction in muscle enzyme activity (glyceraldehyde phosphate, 
lactate dehydrogenase, cytochrome oxidase, and citrate synthetase). The muscle 
biopsies were repeated 3 months later, at which time these changes had almost 
completely resolved.  
 
In summary, acute infection mobilise nutrients, pronominally amino acids from 
skeletal muscle, to satisfy the nutritional requirements of the activated immune 
system. A viral infection also causes an increase in glucagon, cortisol and growth 
hormone, which results in a decreased CHO tolerance and hyper-insulineamia. 
The increased insulin levels reduce the metabolism of fatty acids from the fat 
stores. There is also evidence to indicate that a viral infection causes a 
significant reduction in muscle enzyme activity. 
 
There is some evidence that the oxygen uptake equivalent to the onset of blood 
lactate accumulation of 4mmol per litre decreased by 17% following the viral 
illness. During prolonged exercise at 70% of VO2max, the proportion of energy 
derived from CHO metabolism increased and an inability to maintain 
euglycaemia was observed. The blood lactate values were also significantly 
higher at all stages during a graded exercise test.  
 
 
2.7.8. Summary: Effects of acute URT illness on exercise performance 
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The effects of an acute URT illness on exercise performance in different organ 
systems are summarized in Table 2.7. 
 
Table 2.7. Influence of acute illness on systems of the body, which lead to a 
decrease in exercise performance 
 
System Influence 
Musculoskeletal Muscle wasting (decrease in protein content) 
Decrease in muscle strength (isometric and isotonic) 
Decrease in muscle endurance 
Mitochondrial abnormalities 
Cardiovascular  Decrease in aerobic exercise capacity 
Increase in heart rate at submaximal exercise intensity 
Decrease in stroke volume → Decrease in cardiac output 
Neurological Impairs motor coordination 
Decreased neuromuscular transmission  
Metabolism Catabolism of muscle protein 
Increased uptake of amino acids in the liver and other 
organs 
Decrease in muscle enzyme activity 
Decreased levels of serum fatty acids 
Decreased mobilisation of fatty acids from the fat deports 
Increase in the proportion of energy arriving from CHO 
metabolism 
Higher lactate levels at all stages during a graded exercise 
test 
Increase in glucagon, growth hormone and cortisol 
Hyper-insulinemia  
Decrease in oxygen uptake 
Inability to maintain euglycemia 
 
In summary, an acute URT illness can affect a number of organ systems and 
result in a reduction in exercise performance. Specific detrimental effects on 
tissue structure and function include muscle wasting, impaired motor 
coordination, a decrease in muscle strength (isotonic and isometric) and 
endurance, a decrease in oxygen uptake equivalent to the onset of blood lactate 
accumulation of 4mmol per litre, an inability to maintain euglycemia, increase in 
blood lactate levels, a decrease in aerobic exercise capacity and an increase in 
fatigability. Furthermore, the presence of fever cause a decrease in the body’s 
 49 
ability to regulate temperature, increase fluid losses, decrease stroke volume and 
cardiac output and increase oxygen consumption. 
 
In addition, there is temporary impairment in muscular and cardiovascular 
capacity during exercise (3). It is important for the treating physician and the 
athlete to understand that these and other changes may increase the risk of a 
medical complication if physical exercise is undertaken whilst suffering from an 
acute illness. The medical complications associated with exercise whilst suffering 
from an acute URT illness will now be reviewed. 
 
2.8. Medical complications and risks associated with exercise 
training or competition in athletes with acute URT illness 
 
A number of medical complications can occur in an athlete who performs 
physical exercise (training or competition) whilst suffering from an acute URT 
illness. These complications can vary from a reduction in exercise performance 
(reviewed in section 2.7.), or an increased risk of serious complications, including 
sudden death. It is well documented that sudden death can occur in young 
healthy people who exercised during acute viral illnesses (1). These medical 
complications, which are very important to consider when a treating physician 
advises an athlete whether to continue to exercise with an acute infection, will 
now be briefly reviewed. 
 
2.8.1. Viral myocarditis 
 
Myocarditis is defined as inflammation of the myocardium. Although the 
Coxsackie virus is the most common aetiological factor, and is responsible for 
approximately 50% of cases of viral myocarditis, other viruses including the 
rhinovirus, coronavirus, influenza and cytomegalovirus can also cause 
myocarditis. Bacteria, including the β-haemolytic streptococci, Mycoplasma 
pneumonia and Chlamydia pneumonia can also cause myocarditis. Myocarditis 
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can also be associated with infectious mononucleosis and can also occur as a 
complication after gastroenteritis (3). 
 
The infection may solely affect the heart muscle, or the myocarditis may be part 
of an infection elsewhere in the body, or the myocarditis can be a complication of 
an infection elsewhere in the body. Most commonly, these infections are in the 
upper respiratory tract or digestive system (3). In experimental studies using 
Coxsackie virus mice models, it was found that the myocardial tissue was partly 
affected by the replicating virus, which cause cytolysis and subsequent 
scavenging of infected cells by virus-specific cytotoxic T-cells, and partly affected 
by the action of cross-reactive (autoimmune) cytotoxic T-cells. The infected 
myocardial cells may also cause a shutdown of the metabolism in adjacent non-
infected cells by means of a toxic metabolite (3). 
 
It has been documented that in mice, exercise stress during the early phase of 
Coxsackie myocarditis was associated with an increase in the replication rate of 
the virus within the myocardial cells ((3), (15)). This resulted in an increase in 
tissue damage due to cytolysis, and an enhancement in the immune 
mechanisms, resulting in an increased inflammatory lesion and necrosis (3).  
 
In the majority of cases, myocarditis appears to be subclinical (the patient 
experiences no cardiac symptoms) and a reduction in exercise performance 
might be the only presenting symptom. This subclinical complication of infections 
can be aggravated by physical exertion (3). 
 
Often symptoms of viral myocarditis are vague and non-specific, and can include 
fatigue, fever, myalgia, dyspnoea, chest discomfort (8), a sharp chest pain which 
becomes worse on deep inspiration, chest pain which radiates to the jaw, left 
shoulder and arm and palpitations (most commonly due to ventricular extra-
systoles). An uncommon presentation includes acute congestive heart failure and 
sudden death (3). 
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The findings on physical examination are usually also very non-specific. General 
signs of a viral infection might be present. A tachycardia that is out of proportion 
to the degree of pyrexia is a useful indicator of possible myocardial involvement. 
On cardiac auscultation, the first heart sound may be muffled and an apical 
systolic murmur may be present (8). 
 
There are a number of special investigations that might help with the diagnosis. 
The electrocardiogram (ECG) may show evolving ST-T changes on serial 
recordings (3) a heart block, ventricular arrhythmias, or findings mimicking a 
myocardial infarction (33). Serum concentrations of Troponin T and Troponin I 
will be elevated, the creatine kinase isozyme MB (CK-MB) will be increased, and 
a transient global or regional hypokinesis of the left ventricle and transient 
thickening of the left ventricle wall might be present on an echocardiogram (3).  
 
However, it is important to keep in mind that exercise per se can increase the 
Troponin T levels. It has been indicated that up to 78% of runners who were 
investigated after a marathon had evidence of minor cardiomyocyte damage and 
that previous studies conducted indicated that these changes are likely to be 
physiological (34). It has been shown that the Troponin T level peaks 3 hours 
after exercise and returns to normal baseline levels within 24 hours (34). 
Furthermore, it has been documented that several studies have shown an 
increase in Troponin T and Troponin I levels in athletes following an endurance 
race (35). Despite exercise, there are also other conditions which might increase 
the Troponin levels. These include pulmonary embolism, myocardial infarction, 
sepsis, acute heart failure, amyloidosis and cardiac contusion (35).  
 
It has been documented that several epidemiological studies have shown that 
myocarditis was the presumed cause of 5% of cases of sudden unexpected 
death precipitated by exercise in people under the age of 35 years (3). In 1979-
1992, there was an increased rate of sudden unexpected death amongst 
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Swedish orienteers (16 people) and myocarditis was the most frequent 
histopathological feature. All of them had performed at or close to their maximum 
ability shortly before they died. Therefore, it has been suggested that a 
subclinical myocarditis can be aggravated by physical exertion (15).  
It should be noted that sudden death due to myocarditis is rare and most cases 
of myocarditis resolve without residual symptoms (3). However, myocarditis can  
be associated with the development of an electrically unstable substrate resulting 
in ventricular tachyarrhythmias (33) and the postulated mechanism for sudden 
death of an athlete due to a viral myocarditis, is a fatal dysrhythmia (36). 
 
According to the 36th Bethesda Conference held in 2005, athletes with probable 
or definite evidence of myocarditis should be withdrawn from all competitive 
sports for 6 months after the onset of clinical manifestations. If the left ventricular 
function, wall motion, cardiac dimensions, ECG, and serum markers of 
inflammation return to normal and there is no evidence of arrhythmias on Holter 




Myopericarditis is an inflammation of the myocardium and pericardium, and can 
present with an overlap of symptoms of myocarditis (as discussed above) and 
pericarditis (symptoms including sharp chest pain that is relieved with sitting 
forward and worsened by laying back) (4). The condition is most commonly 
caused by the group B Coxsackie virus, but can also be caused by the 
adenovirus, cytomegalovirus, influenza, echovirus, Epstein-Barr virus, herpes 
virus and parvovirus (4). During influenza, cardiac involvement usually occurs 
during the first week after the onset of symptoms, but there was a case report 
where myopericardial damage occurred on the 10th day after the onset of 
influenza symptoms (4).     
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The condition is usually self-limited, but it has been documented that strenuous 
exercise can markedly accelerate viral myopericarditis and enhance the 




Rhabdomyolysis is the breakdown of skeletal muscle and can be as a result of a 
number of causes (discussed below). During this breakdown process, the 
integrity of the muscle membrane is compromised so that the contents of the 
muscle cell leak into the plasma. This may lead to the accumulation of free 
radicals and tumor necrosis factor-α (TNF-α) in the serum, which then leads to a 
systemic inflammatory reaction (4). The myoglobin released from the muscle 
cells is filtered through the kidneys and excreted into the urine. The myoglobin 
can be directly toxic to the renal tubule and can lead to acute renal failure (37). It 
should be noted that studies have shown that free radicals produced in any 
organ can induce myocardial damage (4). Pro-inflammatory cytokines, including 
TNF-α, are also considered important in the initiation of and development of the 
inflammatory cardiomyopathies and a s such, physicians should be aware that 
exertional rhabdomyolysis may lead to cardiac involvement (4).   
 
There are numerous causes of rhabdomyolysis. These include exercise, 
infection, medications such as statins, alcohol and recreational drugs such as 
cocaine and amphetamine, myopathies and metabolic disorders such as 
hypothyroidism and diabetes mellitus (37).  
 
Clinical features of rhabdomyolysis include acute muscle pain, limb weakness, 
swollen tender muscles, limb weakness, and contractures. Systemic symptoms 
might also be present, which include fever, nausea and vomiting, and 
tachycardia (37). Biochemical findings include an elevation in serum creatine 
kinase (CK) activity, white cell count, potassium, phosphate and urea and an 
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increase in the creatinine: BUN ration. There is a decrease in the calcium and 
albumin levels. Myoglobin is present in the urine (37).  
 
It has been documented that the risk to develop rhabdomyolysis is increased 
when exercising during or after a viral illness (4). In one case report, a healthy 
25-year-old-male presented with symptoms of rhabdomyolysis. The patient had a 
sore throat and cough 10 days prior to the onset of the rhabdomyolysis 
symptoms and influenza A was diagnosed with a rapid test. The patient was 
treated for 5 days with oseltamivir. The patient returned to physical activity 5 
days after the symptoms had resolved. In this case, the patient also had 
myopericarditis, which could have been provoked by the rhabdomyolysis (due to 
the release of the free radicals), but further studies are required to confirm this 
(4). Clinicians treating patients with rhabdomyolysis should however be aware of 
the possible association with acute myopericarditis, especially in the presence of 
a recent influenza A infection. 
 
In another case report, a healthy 36-year-old-male runner collapsed towards the 
end of a half-marathon. The patient’s serum CK levels were 2 975 U/l (elevated) 
on admission to the hospital and peaked at 130 098 U/l, and a diagnosis of 
rhabdomyolysis was made. There was no recent history of an infection, but the 
patient did take a tablet containing ephedrine, which is an indirectly acting 
sympathomimetic amine and is structurally similar to amphetamine (38).  
 
Treating physicians should therefore be aware that cold and flu medicine might 
contain ephedrine or pseudo-ephedrine, and athletes taking these medications 
might thus be at risk to develop rhabdomyolysis when they exercise, either due 
to the infection, or due to the medication. 
 
 
 2.8.4. Sudden death 
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It has been documented that a study of 78 sudden deaths during or immediately 
after exercise indicated that 5 of these individuals suffered from a recent URT 
infection (1). It has also been documented that there are numerous anecdotal 
reports of death in young healthy people who undertook strenuous exercise 
during viral illnesses (1). 
 
2.8.5. Increased duration and severity of symptoms of an illness 
 
There is conflicting evidence whether the duration of illness will be increased and 
the symptoms worsened if a patient exercise whilst suffering from an infection. It 
has been documented that exercising in the presence of an URT illness (with or 
without the presence of a fever), may aggravate the infection by causing more 
pronounced symptoms and/or prolong the length of the illness. The exercise may 
also trigger the development of a complication, such as a pneumonia or 
myocarditis ((2), (3)). 
 
However, in randomised control trail, sedentary participants were followed to 
determine whether exercise affects the severity and duration of a naturally 
acquired URT illness. In this study it was shown that there was no difference 
between the cold symptom score mean values in the exercise and non-exercise 
groups. There was also no difference between the exercise and non-exercise 
groups in the mean number of days from baseline before the subjects were 
asymptomatic. The authors concluded that moderate exercise training in 
sedentary people during a naturally acquired URT illness will not affect illness 
symptom severity or duration (39). In summary, there are data that exercise 
whilst suffering from acute infections may affect the duration and severity of the 
illness, but more research is required in this field. 
 
 
2.8.6. Other medical complications 
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It has been suggested that exercising with an acute infection, may result in   
cardiac dysrhythmias, particularly in the setting of an underlying undiagnosed 
heart condition, such as hypertrophic cardiomyopathy (HCM) (3). It is well 
established that exercise under normal circumstances can trigger a dysrhythmia 
in patients with HCM, but exercising with an underlying febrile infection may 
further increase the risk for the development of an dysrhythmia, as physical 
exertion in the presence of a fever can result in an increased hemodynamic load 
on the heart and precipitate dysrhythmias (3). 
 
As discussed previously infections and fever can affect the nervous system, and 
lead to impairment of coordination. Exercising under these circumstances may 
increase the athlete’s risk to damage a joint, ligaments or tendons, especially 
during sports that demand high precision (3). 
 
Also as previously discussed, a fever affects the body’s ability to regulate body 
temperature. This may lead to an increase in insensible fluid losses which might 
lead to dehydration, and an increase in the risk to develop heat stroke, especially 
if the exercise is performed in a hot and humid climate (2). 
 
Finally, it has been documented that bronchial hyperreactivity may be triggered 
when an individual exercise during an ongoing URT infection (3).   
 
2.8.7. Long-term medical complications: Post-viral fatigue syndrome 
 
One of the most debilitating long term medical complications caused by a viral 
infection is post-viral fatigue syndrome (PVFS), which can persists for months 
(13), or years (1). This is one of the fatigue syndromes (others including chronic 
fatigue syndrome, fibromyalgia and neurasthenia) (40).  PVFS usually occurs 
after a Coxsackie virus infection, but it can also present after infections caused 
by the influenza and varicella viruses (1), or an Epstein-Barr infection (41).  
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Symptoms of PVFS can vary widely and include lethargy, easy fatigability, 
myalgia (13), malaise and myalgia brought on by exertion, sore throat, sleep 
disturbance, loss of concentration, depression and/or anxiety (41), night sweats 
(12) and muscle weakness (40). 
However, in one study the muscle strength and fatigability in a group of 
symptomatic patients were tested 3 months after the onset of a glandular fever-
like illness. The results of this study showed normal strength and fatigability in 
the patients, and the subjective feeling of fatigue could not be explained by 
peripheral changes in muscle isometric force generation or fatigability (40).      
 
2.8.9. Summary: Medical complications and risks associated with exercise 
training or competition in athletes with acute URT illness 
 
It is well documented that there are numerous risks associated with exercising 
whilst suffering from an acute URT illness. Potential complications that can arise 
in the cardiovascular system include viral myocarditis (which will lead to no 
exercise for 6 months), myopericarditis and sudden death. Complications in the 
musculoskeletal system may also occur. Rhabdomyolysis is the breakdown of 
skeletal muscle and this may lead to acute renal failure. Fever can also affect the 
nervous system, which can lead to an impairment of coordination and this can 
lead to injuries of the joints, ligament and tendons. Other potential complications 
include bronchial hyper-reactivity, an increase in the duration and severity of the 
illness, heatstroke and long-term complications such as post-viral-fatigue 
syndrome. A summary of the medical complications and risks associated with 









Table 2.8. Medical complications and risks associated with exercise 
training in athletes with an acute URT illness 
 
System Complication 




Musculoskeletal  Rhabdomyolysis with or without acute renal failure 
Joint, ligament and tendon injuries due to impaired motor 
coordination 
Respiratory system Bronchial hyper-reactivity  
Others Post-viral fatigue syndrome 




2.9. Return-to-play (RTP) guidelines for athletes with acute URT 
illness  
 
Acute URT illness is the most common medical illness that a team physician 
encounters ((1), (5), (6), (7)). Therefore, the most common clinical decision a 
physician, who is responsible for the medical care of athletes, makes, is when an 
athlete can safely return to training or competition. 
 
This important clinical decision has been highlighted more than 30 years ago in a 
case report published in the Lancet in 1982. In this case report, two athletes are 
described. Both athletes presented with symptoms of influenza but opted to 
exercise within a week from the beginning of the symptoms of infection. Both 
athletes suffered from bacterial meningitis and one of the athletes died (29). 
 
Most guidelines recommend that the athlete can safely resume regular training a 
few days after the resolution of symptoms if the athlete had symptoms of a 
common cold only, and symptoms of systemic involvement was absent. If, 
however, there were symptoms or signs of systemic involvement (fever, 
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tachycardia, swollen lymph nodes, extreme tiredness, and myalgia), intensive 
training should be postponed for 2 to 4 weeks ((12), (15)).  
 
Other recommendations are more specific. It has been suggested that rest 
should be advised to an athlete with an infection when fever is present 
(>38°Celcius (C)), or when the individual’s resting temperature has increased by 
0.5 to 1°C or more and their resting pulse rate has increased by 10 beats per 
minute or more in combination with symptoms such as malaise, myalgia, 
arthralgia or headache (3). An acute onset of general malaise, especially in 
combination with pains in the muscles or joints, should also prompt the 
recommendation of rest, even in the absence of a fever (3). In most cases, if a 
fever is present, rest should be recommended until the fever has abated. 
Training can then be gradually resumed and if any symptoms referable to the 
heart appear (chest pain, chest discomfort, irregular heartbeat, abnormal 
breathlessness, abnormal fatigue or exertional syncope), the exercise bout 
should be stopped immediately (3). As these could be the symptoms of a 
myocarditis, a physician should be consulted. When specific symptoms and signs 
are taken into consideration, athletes with a runny nose without a sore throat, 
cough or systemic symptoms and signs, rest should be advised for 3 days, after 
which training can gradually be resumed if the symptoms does not become 
intensified (3). In the athlete with a sore throat without any other symptoms, 
especially systemic symptoms, caution is advised until the sore throat starts to 
improve. If the infection was however caused by a β-haemolytic streptococcal 
bacteria, the athlete should rest until the sore throat has resolved completely, as 
myocarditis may follow the infection (3). Athletes with gastroenteritis should avoid 
physical activity, while exercise should be avoided when a cystitis is present until 
all the symptoms have resolved (3). 
 
To date, the most widely used clinical guideline to determine RTP following an 
acute URT illness is the “neck check” (2). This guideline states that if an athlete 
has symptoms confined to “above the neck”, such as a runny nose, sore throat, 
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sneezing or nasal congestion, the athlete can be allowed to exercise if he or she 
should feel comfortable doing so. Exercise should be attempted at mild to 
moderate intensity for 10-15 min. If the symptoms worsen, the exercise should 
be stopped and the athlete should rest. If, however, the symptoms do not 
worsen, participation should be allowed. If the athlete however has systemic 
symptoms such as fever, swollen lymph nodes, myalgia, coughing, diarrhoea or 
an elevated heart rate, rest should be advised for a period of 7-14 days until the 
symptoms have resolved, due to the risk of serious complications. Once the 
infection had resolved, the athlete should ease back into training, taking one to 
two days for every training day missed to build back up to pre-illness levels. 
 
In summary, current recommendations for contraindications to exercise 
participation in athletes with an acute URT illness are: (8) 
 Presence of fever 
 Presence of myalgia (muscle pain) 
 Presence of chest pain 
 Resting tachycardia  
 Excessive shortness of breath 
 Excessive fatigue 
 Swollen painful lymphadenopathy  
 
It is important to note that certain infections, such as infectious mononucleosis 
(IM) require additional special considerations, as the infection causes an 
enlarged spleen due to lymphocyte infiltration. The enlarged spleen has 
disrupted architecture and this makes it fragile (2). The spleen can rupture if it is 
subjected to a blow or increased pressure (3). Data indicate that 50% of splenic 
ruptures occur without a direct blow to the spleen and the risk of rupture is 0.1-
0.5% (8). The risk for rupture is highest in the first 3 weeks, but is very rare after 
28 days (2). 
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In additional to the general guidelines previously mentioned, athletes with IM with 
splenomegaly should refrain from doing sport for at least 3 weeks. After the 3- 
week period, the athlete may resume low-impact, non-contact training at 50% of 
pre-illness level if there is resolution of symptoms (fever, fatigue, sore throat and 
lymphadenopathy), normalisation of laboratory markers and resolution of 
splenomegaly. If there is no relapse of symptoms and  athlete continues to 
improve in the first week of graded return to exercise, full sport participation, 
including contact sport, may be allowed (2). Full fitness is very often only reached 
after 3 months of training (8). It is important to note that the size of the spleen 
should be evaluated by an ultrasound, as a physical examination of the spleen is 
unreliable to detect splenomegaly (2). 
 
In summary, it has been well documented that acute URT illnesses are the most 
common medical problem an exercise and sport medicine physician will 
encounter. As there are many possible medical complications that can develop 
when an athlete participate in sport when an URT illness is present, physicians 
utilize a clinical guideline called the “neck check” to decide whether an athlete is 
eligible to participate in an exercise session whilst having an URT illness. The 
guideline stipulates that an athlete can participate in sport when symptoms and 
signs are local (blocked nose, runny nose, sore throat, erythematous throat) and 
symptoms and signs of systemic involvement (fever, tachycardia or resting heart 
rate increase by 10 beats or more, myalgia, malaise, lymphadenopathy, cough, 
chest pain and shortness of breath) is absent. If systemic symptoms are present, 
rest should be advised for 7 to 14 days. If the athlete “pass the neck check” and 
are allowed to exercise, or when the athlete returns from an illness, exercise 
should be resumed at moderate intensity for 10-15 minutes. If any symptoms 
return or are worsened by the exercise, the exercise session should be stopped 
and further rest should be advised.  
 
Special considerations are required for a few conditions. Firstly, no exercise 
should be allowed when the athlete has cystitis or gastroenteritis. Secondly, 
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when an athlete has infectious mononucleosis, non-contact sport should only be 
considered after 3 weeks and contact sport after 4 weeks of rest, as the enlarged 
spleen is at risk to rupture within this time frame. The athlete may only participate 
in sport once symptoms have abated and the spleen has regressed to its normal 
size (proven by sonography). Exercise should be resumed at 50% of the pre-
illness level of intensity and volume for 1 week. If the athlete continues to 
improve, full training may be resumed.  
 




Athletes often lose weeks of training each year due to acute illnesses, of which 
URT illness is the most common. An athlete may also miss that all-important race 
for which months of preparation has gone into, due to an URT illness. It is for this 
reason that prevention of illness is of utmost importance. The following 
preventative measures will be briefly reviewed in this section:  
 Personal hygiene 
 Nutritional strategies 
 Probiotics  
 Other strategies. 
 
2.10.2. Personal hygiene 
 
Personal hygiene is not only the most important, but also the most practical and 
easiest preventative strategy. Most URT infections are transmitted through 
airborne droplets (sneezing and coughing) and by contact (direct skin contact or 
indirect contact with sporting equipment) (3). As such, there are preventative 
measures that can reduce transmission. 
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The most important preventative measure is frequent hand washing ((1), (2), 
(27)), and avoiding contact between the hands, eyes and nose, as this is a 
primary route of introducing viruses into the body (12). Other measures include 
covering the mouth and nose with the cubital fossa when sneezing or coughing 
(27), avoiding direct skin-to-skin contact (1), and avoiding contact with ill 
individuals ((2), (12)). Sharing of water bottles, towels and sporting equipment 
should be strongly discouraged ((1), (2)). 
 
In summary, the following personal hygiene strategies should be followed to 
prevent an URT illness: 
 Avoid contact with people who are ill 
 Wash hands frequently 
 Avoid putting hands to eyes and nose 
 Do not share water bottles, towels or sporting equipment 
 Avoid skin-to-skin contact 
 
2.10.3. Nutritional strategies 
 
Nutrition is an important preventative measure. Various nutritional components 
will be briefly reviewed in this section, including vitamins, glutamine, cysteine and 






It has been shown that vitamin C supplementation may reduce the risk of 
symptoms of acute URT illness in distance runners. In one double-blind, placebo 
controlled study that was conducted on 92 runners who had entered the 1990 
90km Comrades Ultra-Marathon in South Africa, daily supplementation with 
600mg vitamin C reduced the incidence of post-race URT illness, from 68% to 
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33% (p<0.01) (42). A limitation to this study is that the URT illnesses were never 
proven to be infectious. Furthermore, whether vitamin C supplementation 





In one prospective cohort study, the influence of vitamin D status on the 
incidence of respiratory illness and immune function during a 4 month (16 week) 
winter training period in endurance sport athletes was examined (43). In this 
study, 225 participants were divided into a vitamin D deficient group (plasma 
25(OH)D < 30nmol/L), an inadequate vitamin D group (plasma 25(OH)D 30-
50nmol/L) and an optimal vitamin D group (plasma 25(OH)D > 120nmol/L). The 
results of this study showed that, after 16 weeks, a significantly higher proportion 
of participants presented with symptoms of an URT illness in the vitamin D 
deficient group compared with the optimal vitamin D group (deficient group 67%, 
optimal 27%; P=0.039). The total number of URT illness symptom days (optimal 
5, deficient 13; P=0.059) and the median symptom-severity score (optimal 43, 
deficient 102; P=0.013) in the vitamin D deficient group was also significantly 
higher than in the other groups. Finally, saliva secretory immunoglobulin A (SIgA) 
secretion rate in the optimal vitamin D status group was also significantly higher 
than the other groups (optimal 38.7µg/min, inadequate 19.5µg/min, deficient 
23.6µg/min; P=0.018).  
 
This study indicated that vitamin D status could influence URT illness symptom 
incidence, the duration of an illness episode and the severity of symptoms. An 
optimal vitamin D level has more favourable outcome by lowering the incidence, 
shortening the episode and reducing the severity. The study also indicated that 
an optimal vitamin D level increased the secretion rate of salivary IgA, which 
functions as a first line of defence against pathogen invasion. It is known that 
there is an inverse relationship between salivary IgA values and URT illness 
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prevalence and as such, vitamin D supplementation might enhance the 
prevention of an URT illness in athletes.  
 
2.10.3.2. Glutamine  
 
Glutamine is a naturally occurring non-essential neutral amino acid and is the 
most abundant free amino acid in human muscle and plasma (44). It is an 
important fuel for the immune system, as lymphocytes and macrophages utilise 
glutamine at high rates and are dependent on glutamine for replication. 
It was postulated than when plasma glutamine concentration decreases below a 
physiologically normal range (0.5-0.9Mm), limited glutamine availability may 
impair certain immune cell functions and increase an individual’s susceptibility to 
infections such as URT infections (45).  
 
It has been suggested that a reduction in plasma glutamine concentration, 
associated with period of heavy training, could be partly responsible for immune 
suppression in endurance athletes and that immune function could be impaired 
by the reduction intramuscular and plasma concentrations of glutamine, 
associated with prolonged exercise (44). 
 
It was postulated that oral supplementation with glutamine should prevent the fall 
in plasma glutamine concentration after exercise and thus prevent the associated 
post-exercise immune impairment, if the reduction in plasma glutamine 
concentration indeed was a causal factor in the transient post-exercise 
depression in immune function (44). However, several glutamine 
supplementation intervention studies showed that glutamine supplementation 
before and after exercise has no detectable effect on exercise-induced changes 
in immune cell functions (44). It was documented that in one randomized, cross-
over, placebo-controlled study, participants performed 3 consecutive bouts of 
cycle ergometer exercise at 75% VO2max for 60, 45 and 30 minutes with 2 hours 
rest in between each bout (44). The participants ingested 0.1g/kg body mass 
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glutamine 30 minutes before the end of each exercise bout and 30 minutes after 
each exercise bout.  Although the glutamine supplementation prevented the 
reduction in the plasma glutamine concentration, it did not prevent the reduction 
in lymphocyte proliferation or the decrease in NK-cell activity. 
 
It has been documented in a review that an acute exercise bout and intense 
training cause a reduction in salivary IgA concentrations (8). The levels return to 
the normal range within 1 hour after cessation of the exercise. However, maximal 
exercise bouts may prolong the return to normal values and repetitive exercise 
bouts during periods of heavy training may result in a cumulative reduction in 
salivary IgA concentrations which can predispose the athlete to URT infections 
(8). Intense exercise may induce small transient decrements in plasma glutamine 
concentrations, which results in a reduction of glutamine supply to the mucosal 
tissues secondary to a decrease in glutamine availability. Repetitive reductions in 
glutamine supply to IgA-producing lymphoid cells could affect their ability to 
produce IgA and this can lead to an increased susceptibility to infection (45). 
 
Theoretically, chronic glutamine supplementation would help maintain glutamine 
homeostasis and secretory IgA (sIgA) concentration. However, in one study 
conducted on 13 healthy runners, it was documented that chronic, high-dose 
glutamine supplementation during 9 days of interval training had no effect on 
salivary IgA concentration or output. It did however resulted in a higher nasal IgA 
during training (of which the biological significance is uncertain) (45).  
 
In summary, the available evidence is thus not strong enough to warrant a 
recommendation for an athlete to use a glutamine supplement to prevent URT 
illness. It should be noted though that there are some suggestions of a possible 
role for glutamine in stimulating anabolic processes, including muscle glycogen 




2.10.3.3. Cystine and Theanine 
 
Cystine is a dipeptide of cysteine and a precursor of glutathione, which is 
responsible for the anti-oxidative response inside the body. Theanine is an amino 
acid that is metabolised to glutamic acid and ethylamine within the intestinal tract, 
liver and kidneys. One study reported that oral administration of cystine and 
theanine improved antibody production in the elderly, and this lead to a 
randomised, double-blind, placebo-controlled, parallel-group study in 15 male 
long-distance runners (46). Eight participants were assigned to a 
cystine/theanine group who ingested 700mg of cystine and 280mg of theanine 
per day for 10 days prior to a summer training camp. The athletes ran an 
average of 15.2 km/day in the 10-day period prior to the camp and 18.1 km/day 
during the 11-day training camp. The study showed that ingestion of cystine and 
theanine prevented a reduction in the leucocyte count after the training camp 
(which was observed in placebo group), and prevented an increase in the 
neutrophil count and high sensitive CRP after the camp (which was also 
observed in the placebo group). The study thus suggests that oral 
supplementation with cystine and theanine prevented changes in the 
inflammatory responses after prolonged, intense endurance exercise, as well as 
preventing lowering of the immune function, and contributed to the prevention of 
infection as well as reducing their symptoms. 
 
2.10.3.4. Carbohydrate ingestion during exercise 
 
It has been documented that CHO ingestion by endurance athletes during 
intensive exercise is associated with an attenuated cortisol, growth hormone, and 
epinephrine response, fewer perturbations in blood immune cell counts, lower 
granulocyte and monocyte phagocytosis and oxidative burst activity, and a 
diminished pro- and anti-inflammatory cytokine response compared to placebo 
ingestion (47). In a review of 66 placebo-controlled and/or crossover trials, it was 
evident that the consumption of ≥ 6% CHO (1 litre per hour) during prolonged 
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exercise was an effective approach to maintain immune function in athletes. This 
might be due to the attenuating effects on the exercise-induced increases in total 
leukocyte counts and/or leukocyte subsets such as monocytes and neutrophils. 
The ingestion of ≥ 6% CHO also attenuates cytokine changes in response to 
prolonged exercise, in particular interleukin 6 and 10, and maintains blood 
glucose levels, which leads to an attenuated post-exercise cortisol level, resulting 
in a less suppressed immune function (21). There was however no mention in 
the review that the maintenance of the immune function translates into a 
reduction in URT illness symptoms.   
 
In conclusion, there is some evidence that ingestion of ≥ 6% CHO during 
prolonged exercise can maintain the immune function, but more research is 
required to prove that this translate into the reduction of URT illness. 
 
2.10.4. Probiotics  
 
There is increasing evidence from a double-blind, randomised controlled trial and 
meta-analysis of randomised, placebo-controlled trials that probiotic 
supplementation can reduce the number, duration and severity of acute 
infectious diarrhoea and URT infection in the general population (48). 
Furthermore, it has been documented that probiotics may reduce gastrointestinal 
illness in endurance athletes (48). Recently, there are some data from a double-
blind, placebo-controlled, crossover trail that indicate that probiotic 
supplementation (Lactobacillus fermentum VRI-003) (PCC) might be useful for 
reducing the duration of URT infections and the severity of the respiratory illness 
in elite athletes (49).  
 
In a randomised, double-blind, placebo-controlled study 88 healthy, physically 
active participants were included in a study to determine the effects of 
supplementation with Lactobacillus fermentum (PCC®) on URT infections and 
gastrointestinal symptoms over a 15-weeks winter training period (48). The 
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participants were divided into either a probiotic or placebo treatment group and 
consumed a capsule on a daily basis. The participants recorded gastrointestinal, 
URT and lower respiratory tract symptoms on a daily basis on an illness-log for 
the duration of the study (15 weeks). Two or more symptoms on 2 consecutive 
days were defined as an illness period.  
 
The study showed a 2-fold increase in the number and duration of mild (low-
grade) self-reported gastrointestinal symptoms in both male and females taking 
the probiotic. However, in the male participants, the self-reported severity score 
of gastrointestinal illness was lower compared to the males in the placebo group 
and this positive effect increased with higher training loads. 
The effects of the probiotic supplementation on URT illness was however unclear 
in both male and females. In the male participants taking the probiotic, the 
number, duration and severity of lower respiratory tract infections were 50% 
lower compared to the males in the placebo group. However, in female 
participants in the probiotic group, there was a 2-fold increase in the number and 
duration of lower respiratory tract infections compared to the participants in the 
placebo group, but the severity was reduced.  
 
In conclusion, there is good evidence that that probiotic supplementation can 
reduce the number, duration and severity of acute infectious diarrhoea and URT 
infection in the general population. However, some conflicting evidence exists 
pertaining to the effect a probiotic may have on elite and endurance athletes. 
Some data indicate that probiotics may reduce the duration of URT infections 
and the severity of the respiratory illness in elite athletes and probiotics may 
reduce gastrointestinal illness in endurance athletes. Other data indicate that 
probiotics only decreased the severity of gastrointestinal illness in male athletes 
(not the number of episodes), decreased lower respiratory tract illness episodes 
and severity in male athletes only, and the effect on URT illness in male and 
female athletes was unclear. More research is necessary in this field. 
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2.10.5. Other preventative strategies 
 
Other preventative strategies that are aimed at reducing the risk factors 
associated with an increased incidence of URT illness include the following: 
 Eating a well-balanced diet is important, as inadequate nutrition may 
contribute to impaired immunity because normal function of the immune cells 
requires an adequate amount of water, electrolytes, glucose and proteins ((1), 
(2), (8), (12), (21)). 
 Rapid weight loss (more than 1% of body weight per week) should be 
avoided, as it has been linked to negative immune changes, especially T-cell 
suppression (12). 
 Sleep disruption has also been linked to immune depression (12). An effort 
should thus be made to get adequate sleep ((1), (2), (8)). 
 There are many reports of URT illness resulting from increased training, and 
also in overreached and overtraining syndrome athletes (24). It is thus 
important to avoid overtraining and fatigue ((1), (2), (8), (12)). 
 A single session of strenuous endurance exercise is followed by temporary 
functional immunodepression (as discussed in section 2.4.1.1). If resting 
periods between such exercise sessions/ competitions are not long enough to 
allow the immune function to recover, the athlete is at an increased risk of 
becoming ill. It is thus important to space high intensity and prolonged 
exercise sessions and races as far apart as possible ((1), (2), (3), (8)). 
 Mental stress has been linked to an increased risk for URT illness (12). It is 
thus important to reduce life stressors ((1), (2)). 
 Vaccinations are available to prevent illness caused by influenza viruses and 
it is strongly recommended to obtain these during the winter months ((1), (2), 






2.10.6 Summary: Preventative strategies 
 
Numerous preventative strategies have been proposed in an attempt to reduce 
the incidence of URT illness and gastrointestinal disorders in endurance athletes.  
Personal hygiene is by far the most important strategy. Nutrition has been 
proposed as a possible measure to prevent illness. Vitamin C supplementation 
was proven to prevent post-race illness, but further research is required to 
investigate its potential to prevent pre-race illness. It has been recognized that 
vitamin D plays an important role in upregulating immunity (43) and it has been 
shown that vitamin D supplementation might enhance the prevention of an UTR 
infection in athletes. Glutamine is an important fuel for the immune system and it 
has been postulated that prolonged exercise is associated with a decrease in 
intramuscular and plasma concentrations of glutamine. However, the currant 
available evidence is not strong enough to warrant a recommendation of 
glutamine supplementation to prevent URT infections in athletes. There is some 
evidence that cystine and theanine supplementation prevents changes in the 
inflammatory response associated with prolonged, intense endurance exercise, 
and prevents lowering of the immune function. Supplementation was proven to 
contribute to the prevention of infection as well as reducing their symptoms in 
endurance athletes. There is some evidence that the consumption of ≥ 6% CHO 
(1 litre / hour) during prolonged exercise results in a less suppressed immune 
function. However, more research is required to prove that this translate into the 
reduction of URT illness. Probiotics have been studied as a possible preventative 
measure for URT illness in athletes. Conflicting evidence exist, as some data 
indicate that probiotics may reduce the duration of URT infections and the 
severity of the respiratory illness in elite athletes and probiotics may reduce 
gastrointestinal illness in endurance athletes. Other data indicate that probiotics 
only decreased the severity of gastrointestinal illness in male athletes (not the 
amount of episodes), decreased lower respiratory tract illness episodes and 
severity in male athletes only, and the effect on URT illness in male and female 
athletes was unclear. More research is necessary in this field. Other preventative 
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strategies include eating a well-balanced diet, avoiding rapid weight loss, getting 
adequate sleep, avoiding overtraining and fatigue, reducing life stressors and 
spacing high intensity and prolonged exercise session and races as far apart as 
possible.  
 
2.11. Summary: Acute illness in athletes with specific reference 
to acute pre-race illness in distance runners 
 
  Epidemiological data indicate that endurance athletes undergoing intense 
and prolonged training are at increased risk for URT illness. 
  However, there are little data on the incidence of URT illness in runners 
prior to an endurance race, but in two studies at marathons this appears 
to be high (between 17% and 40%) ((14), (18)).  
  Most data on the incidence of URT illness in runners are based on self-
reported questionnaires and there is no evidence that these URT 
illnesses were in fact due to infection.  
  Other conditions such as allergic rhinitis, asthma, thyroiditis, and gastro-
oesophageal reflux as causes of symptoms of URT illness should be 
considered.   
  More research to determine the incidence of a clinically diagnosed URT 
infection in runners (prior to and after an endurance race) is required.  
  The relationship between the “dose of exercise” and the risk of URT 
illness symptoms is a “J-shaped” curve. 
  Individuals who exercise at moderate intensity and duration having the 
smallest risk to develop an URT illness, while sedentary individuals have 
a higher risk to develop an URT illness. 
  Endurance athletes training at high intensity and prolonged duration have 
the highest risk to develop an URT illness (8).  
 There are a number of changes in immune system parameters after an 
acute exercise bout and these last for 3-72 hours. 
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  This is known as the “open window” period and may be associated with 
an increased risk of susceptibility to illness. 
  Numerous risk factors to develop an URT illness in distance runners have 
been identified.  
  Intrinsic risk factors include exercising after a recent URT infection, low 
sIgA, BMI > 75th percentile and being a female. 
  Extrinsic risk factors include a training distance > 65km/week, training at 
intensities > 50-75% of maximum ability, training duration > 90 min per 
session, inadequate recovery time between heavy exercise bouts, stress, 
fatigue, inadequate sleep, inadequate calorie and CHO intake and 
exercising without food and in a dehydrated state. 
  Infections, including URT infections, have a detrimental effect on several 
systems in the body, including the cardiovascular, neurological, muscular, 
thermoregulatory and metabolic systems.  
  Exercising whilst suffering from an URT infection can be associated with 
a number of medical complications. 
  These complications include myocarditis, myopericarditis, 
rhabdomyolysis, post-viral-fatigue syndrome, dysrhythmia, heat stroke, 
bronchial hypersensitivity and even sudden death. 
  Currently, advice whether an athlete can participate in sport whilst being 
ill, is based on a clinical guideline known as the “neck check”. 
  However, there are very few studies in the literature to validate this 
guideline. 
 Currant return-to-play (RTP) guidelines can be summarized as follows: 
 In all infections, rest should be advised for the first 3 days, as the 
symptoms might be part of a prodromal phase of a more sinister 
infection, such as a meningitis or rubella. 
 If the athlete experienced symptoms, which would have passed the 
“neck check”, i.e. local symptoms/signs are present and systemic 
symptoms/signs are absent, exercise should be allowed when the 
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athlete feels comfortable doing so. Exercise should however be 
attempted at 50% intensity for 10-15 minutes and if symptoms 
worsen or if symptoms referable to the heart appear (chest pain, 
chest discomfort, irregular heartbeat, abnormal breathlessness, 
abnormal fatigue or exertional syncope), the exercise bout should 
be stopped immediately and further rest should be advised. 
 If a sore throat is present and a β-haemolytic streptococcal bacteria 
is suspected, rest should be advised until the symptom has 
subsided completely, as myocarditis may follow a sore throat 
caused by a β-haemolytic streptococcal bacteria.   
 If systemic symptoms are present, rest should be advised for 7-14 
days and once the infection had resolved, the athlete should 
resumed exercise at mild to moderate intensity for 10-15 min. If 
symptoms worsen or if symptoms referable to the heart appear 
(chest pain, chest discomfort, irregular heartbeat, abnormal 
breathlessness, abnormal fatigue or exertional syncope), the 
exercise bout should be stopped immediately and further rest 
should be advised. 
 Contraindications to exercise participation in athletes with an URT 
illness fever, resting tachycardia (or pulse rate which has 
increased by ≥ 10 beats / min, myalgia (muscle pain), swollen 
painful lymph glands, coughing, shortness of breath, excessive 
fatigue, and chest pain. 
 
 RTP guidelines in athletes with infectious mononucleosis require special 
consideration, as there is an increased risk for spontaneous splenic 
rupture during the first 3 weeks of the illness. Non-contact sport is allowed 
after 3 weeks of rest. Training should be commenced at 50% of the 
training load prior to the illness and full fitness is only expected after 3 
months. Contact sport may only be resumed after 4 weeks of rest and 
after splenomegaly was excluded by an ultrasound (8). 
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 Strategies to prevent URT illness have been proposed and include the 
following: personal hygiene (hand washing, avoiding ill people, avoid 
sharing water bottles and sporting equipment, avoid skin-to-skin contact, 
avoid putting hands to eyes and nose), nutritional strategies (vitamin C 
and D supplementation, glutamine supplementation, cystine and theanine 
supplementation, and adequate CHO intake during prolonged training 
sessions), probiotics supplementation, and other preventative strategies 
(including eating a well-balanced diet, avoiding rapid weight loss, avoiding 
overtraining and fatigue, getting adequate sleep, spacing of heavy 
exercise sessions as far apart as possible, immunization, decreasing of 
life stressors).  
  In conclusion, very little data is available in the literature to validate the 
clinical guidelines that are used by physicians, and applied by athletes, in 
an attempt to minimize the possible medical complications when 
exercising with an infection or illness.  
 More studies need to be conducted to determine if current guidelines are 
adhered to, and if information given to athletes can alter their decision to 










An acute pre-race illness screening and educational 
intervention program effectively reduces the number of 
runners starting a race, thereby preventing any 
increased risk of not finishing the race, or risk of 





It has been well established that the most common acute illnesses affecting 
athletes are upper respiratory tract (URT)  illnesses, followed by gastrointestinal 
diseases and skin disorders ((1), (5), (6), (7)). It has been documented that an 
athlete is at an increased risk to develop an upper respiratory tract illness during 
periods of high intensity (about 75% -80% of maximum ability) and prolonged (> 
60min) training sessions (8). High intensity and prolonged duration training 
sessions are associated with a decreased immunity, which can last 3 to 72 
hours. This period is referred to as the “open window” period and it is during this 
period that the athlete is particularly vulnerable to contract an illness ((3), (8), 
(12), (13) (21)). 
 
There are also data suggesting that athletes, participating in endurance events, 
such as marathons and ultra-marathons, have an increased risk of developing an 
URT illness in the period after the event ((2), (8), (12), (13), (14)). It has been 
shown that a runner has a 100-500% increased risk to develop an URT illness 
after an ultra-marathon (16). Runners with a high training load (>65km per week) 
(8), fast marathon time ((8), (17)) and those who had a recent pre-race illness 
(18), have the highest risk of developing a post-race URT illness. 
 
However, data on the prevalence of an acute illness in the immediate pre-race 
period are limited and vary. One study indicated that 17% of runners participating 
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in the 2000 Stockholm Marathon had an illness episode in the 3 weeks prior to 
the race (18). Another study indicated that 40% of runners participating in the 
1987 Los Angeles Marathon reported an URT illness in the 8 weeks prior to the 
marathon (14). Although limited, these data therefore indicate that a significant 
number of runners have symptoms of an acute illness in the period immediately 
before a race, and these are mostly respiratory tract illnesses. 
 
The effects of an acute illness on exercise performance and the possible medical 
complications when exercising with an illness, particularly if the illness is as a 
result of an acute infection have been reviewed in Chapter 3 (Sections 2.7. and 
2.8. respectively). These complications can be life threatening and have been 
associated with an increased risk of sudden death due to myocarditis (3). 
 
One of the most common clinical decisions for the sport and exercise medicine 
physician is the return-to-play following an acute illness. Currently, clinicians use 
a clinical tool, the “neck check”, to asses and then advise an athlete with an 
acute illness to either participate in an event (or exercise session) or not (9). 
According to this clinical guideline athletes are advised not to participate if there 
are any systemic symptoms (fever, myalgia, chest pain, resting tachycardia, 
excessive shortness of breath, excessive fatigue, or swollen painful 
lymphadenopathy). This guideline does allow participation at lower exercise 
intensity, with ongoing monitoring of symptoms, if athletes suffer only from 
“localized” URT symptoms (runny nose, blocked nose, sore throat).   
 
However, as far as we could ascertain, there are currently no studies to validate 
the “neck check” clinical guideline. More specifically, it is not clear 1) what the 
prevalence of athletes with symptoms of an acute illness is in the 1 week-period 
prior to an endurance race, 2) how many athletes would adhere to advice given 
by their medical doctor using the “neck check” symptom guideline, 3) whether 
athletes with symptoms of an acute illness prior to the race, and then continue to 
 78 
participate in the race either are not able to complete a race, or suffer from any 
medical complications during or immediately after the race.  
 
3.2. Aim of the study 
 
The aim of this study was to determine 1) the period prevalence of runners with 
symptoms of an acute illness one week prior to the 2012 Two Oceans endurance 
running races (21km and 56km), 2) the period prevalence of runners who “fail” 
the “neck check” and therefore would be advised not to participate in the race, 3) 
the incidence of runners with symptoms of an acute illness (and who then 
received educational material) that did not start the race, 4) the incidence of 
runners with symptoms of an acute illness ( and who then received educational 
material) that started, but not finish the race, and 5) the incidence of runners with 
symptoms of an acute illness (and who then received educational material) that 
started, but develop medical complications during the race.    
 
3.3 . Methods 
 
3.3.1. Type of study 
 
This was a prospective cohort study. 
 
3.3.2. Selection of participants 
 
Prior to the onset of the study, the Research Ethics Committee of the Faculty of 
Health Science at the University of Cape Town approved the protocol (HREC 
REF: 009/2011) (Appendix C). All the athletes (n=25455) who entered the 2012 
Old Mutual Two Oceans ultra-marathon (56km) and half-marathon (21km) in 
Cape Town, South Africa, were regarded as potential participants for the study.  
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All the potential participants were informed about the study, which was part of a 
larger study on reducing medical complications during running. All runners who 
entered for the Two Oceans half-marathon and ultra-marathon races (n=25455) 
and who gave informed consent to receive further email communication were 
contacted in the 5 days prior to the race. All these runners received information 
and a pre-race acute illness questionnaire to complete (Appendix A).  
 
However, as not all runners had access to email during the pre-race period, an 
additional opportunity was created for these runners to complete the pre-race 
acute illness questionnaire at the registration expo during the 3-day period prior 
to the race. At the time of the pre-race expo that was held during the 3-day pre-
race period, runners who gave verbal consent could also complete a pre-race 
acute illness questionnaire during interviews by medical staff of the research 
team. These interviews were held while runners were finalizing their registration 
for the race. Samsung electronic tablets were used to log the answers and the 
data was submitted electronically and added to the database from the responses 
that were received via the email.  
 
Of the total number of runners registered for either 56km or 21km race 
(n=25455), a total of 7992 runners completed the pre-race acute illness 
questionnaire (6907 through email communication, and 1085 during pre-race 
interviews). Of the 6907 runners who completed the questionnaire by email, 5954 
completed the registration process and could run in the race. Therefore, the final 
cohort of runners who completed the pre-race acute illness questionnaire for this 
study was 7035 (5954 by email, and 1085 by interviews). The cohort of runners 
therefore represented 27.6% of all the race entrants (7035/25445).   
 
3.3.3. Pre-race acute illness questionnaire 
 
The pre-race acute illness questionnaire (Appendix A) was preceded by a 
paragraph explaining the importance of acute illness prior to a race. This was 
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followed by a brief description of any possible symptoms of an acute infective 
illness as follows: 
“The symptoms of infections vary but include the following: generally not 
feeling well, fever, general muscle pain, general joint pain, general 
tiredness, headache, sore throat, blocked or runny nose, sore ears, 
cough, wheeze, diarrhoea, nausea, vomiting, or abdominal pain”. 
 
This description was then followed by a single question to ascertain whether the 
runner experienced any symptoms of an acute illness in the 7-day period prior to 
the race as follows: 
Do you have any of these symptoms of acute illness (today or in the last 7 
days)?           Yes       No 
 
If a runner selected the “No” option they were notified “to enjoy the race”. If they 
selected the “Yes” option, additional choices were given. Runners were asked to 
select (one or more) symptoms they experienced form a list. These symptoms 
were as follows: systemic symptoms (fever; cough; general muscle pain), 
respiratory symptoms (sore throat; runny nose; blocked nose), gastrointestinal 
symptoms (nausea; vomiting; diarrhoea; abdominal pain), bladder infection, skin 
rash and other symptoms. Once they indicated which symptoms they 
experienced, an automated email was sent to them with an information leaflet 
attached to it. 
 
3.3.4. Educational intervention 
 
Runners who indicated that they experienced symptoms of an acute illness were 
given educational information (Appendix B) with general information about acute 
illness, information about the risk to exercise with the illness, and specific 
guidelines on when not to participate while certain symptoms are present. 
Runners with symptoms received one of three leaflets, depending on the 
symptoms runners listed in their responses: 1) specific advice on respiratory tract 
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infections and running, 2) specific advice on gastro-intestinal illness and running, 
or 3) general advice on acute infections and running for non-specific infective 
symptoms (Appendix B). The information leaflets were distributed by an 
automated email system (for the email communication) or given as a hand-out 
(following the interview). 
 
3.3.5. Runner follow-up on race day 
 
All the runners were followed during race day. Information about each runner 
was obtained from a database of the race organizers. Data obtained related to 
runners who actually started the race and which of the athletes who started the 
race, finished the race. These data was obtainable because each runner was 
required to wear an electronic chip (“Champion” chip) that was strapped to their 
running shoes which contains information about the runner. These chips 
activated a signal when the athletes passed over a mat as they crossed the 
starting line and finish line. A runner was considered to be a “non-starter” if the 
start-line mats did not capture a start time on race day. Similarly, a runner was 
considered a “non-finisher” if the finish-line mats did not capture a finish time on 
race day. 
 
Data were also obtained from the medical stations on route and the medical tent 
at the finish line. Runners who developed any medical complication during the 
race were treated at these facilities. However, all runners who voluntarily 
withdrew from the race did not necessarily report to the medical facilities. Each 
runner who was admitted to the medical facilities was scanned (their race 
number was obtained) at the entrance to the facility and each runner was 
scanned out again as they left the medical facility. Their final diagnosis (ICD-10 
code) was logged electronically against their race numbers on Samsung 
electronic tablets. All runners who were treated at a medical facility were 
considered to have a medical complication.  
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3.3.6. Measures of outcome 
 
The main measures of outcome of the study were as follows: 
 The period prevalence (%) of runners with symptoms of an acute illness in 
the 7-days prior to an endurance race 
 The did-not-start (DNS) rate (% runners) in runners in different groups 
 The did-not-finish (DNF) rate (% runners) in runners in different groups 
 The medical complication (MC) rate (% runners) in runners in different 
groups 
 
3.3.7. Analysis of data and sub-groups 
 
As previously indicated, runners could select one or more symptoms of acute 
illness in the illness questionnaire (Appendix A). Based on the response to the 
pre-race acute illness questionnaire, runners were firstly categorized into an 
asymptomatic control group (n=5697) (81% runners), and a symptomatic group 
(including all the runners with any symptoms of an illness) (n=1338; 19%). 
 
Runners in the symptomatic group were further divided into sub-groups as 
follows: systemic symptoms group (n=530), respiratory symptoms group (n=896), 
gastrointestinal symptoms group (n=249) and runners who failed the “neck 
check” (n=878).  
 
3.3.8. Statistical analysis of data  
 
All data were entered into an Excel spread sheet (Microsoft 2010) and analysed 
using the SAS (V9.3) statistical package (SAS Institute Inc, Cary, North Carolina, 
USA).  Most of the data were analysed in two-way tables, using two-tailed Chi-
square tests with Yates’ correction factor to calculate p-values.  In some cases, 
numbers were too small with <5 data in a field; a Fisher’s exact test was then 
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used to calculate probability values of p.  P-values of <0.05 are considered 




3.4.1. Period prevalence (%) of runners with symptoms of an acute illness 
in the 7-days prior to an endurance race 
 
Of the 7035 runners, 5697 runners (80.89%) reported no symptoms in the 7 days 
prior to the race, while 1138 runners (19.02%) did experience symptoms of an 
acute illness in the 7-day period prior to the race. The frequencies of the 
symptoms experienced by the athletes can be viewed in Table 3.1. The most 
common symptom experienced by the runners was a sore throat (34.5%), 
followed by a runny nose (29.9%), general tiredness (27.8%), a blocked nose 




Table 3.1. Frequencies of symptoms experienced by runners one week 




Number of  
athletes  
Percentage 
(of 1338 athletes) 
Sore throat 452 34.5% 
Runny nose 392 29.9% 
General tiredness 365 27.8% 
Blocked nose 305 23.3% 
Headache  296 22.6% 
General muscle pains 282 21.5% 
Cough  243 18.5% 
diarrhoea 154 11.7% 
General joint pains 149 11.4% 
Fever 105 8% 
Sore throat 98 7.5% 
Abdominal pain 98 7.5% 
Nausea   65 5% 
Wheezing 48 3.7% 
Bladder infection 40 3.1% 
Skin rash 16 1.2% 
Vomiting 15 1.1% 
 
When these symptoms experienced by the runners during the week prior to the 
race were grouped into clusters of symptoms, 530 runners (7.5%) experienced 
acute systemic symptoms, 896 runners (12.7%) experienced acute respiratory 
symptoms and 249 runners (3.5%) experienced acute gastrointestinal symptoms. 
In addition, 6157 runners (87.5%) passed the “neck check”, while 878 runners 
(12.5%) failed the check. 
 
3.4.2. The did-not-start (DNS) rate (% runners) in different groups 
 
In the cohort of 7035 runners, 6535 runners (92.9%) started the race and 500 
runners (7.1%) did not start the race. Of the 500 runners who did not start, 355 
runners did not experience any symptoms of an acute illness in the 7 days prior 
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to the race, while 145 runners did experience symptoms of an acute illness 
during the 7-day period prior to the race.  
 
The did-not-start (DNS) rate (% runners) in different groups and sub-groups is 
depicted in Table 3.2. The DNS rate for the control group (asymptomatic runners) 
was significantly lower (6.2%) and the DNS rate for the symptomatic group 
(10.8%) (p<0.0001).  
 
In the sub-groups of symptomatic runners, the DNS rate for the runners with 
systemic symptoms was highest (14.7%), and this was significantly higher than 
the control group (p<0.0001). Runners who experienced gastrointestinal 
symptoms also had a high DNS rate of 12.1% (p=0.0003 vs. the control group), 
while runners who experienced respiratory symptoms had a DNS rate of 11.7% 
(p<0.0001 vs. the control group). Similarly, the DNS rate for the runners who 
failed the “neck check” was 12.2% (p<0.0001 vs. the control group).  
 
Table 3.2. The did-not-start (DNS) rate (% runners) in different groups and 
sub-groups   
 
Group Sub-group Percentage of 
runners 
P-value * 
Control group  6.2%  




























3.4.3. The did-not-finish (DNF) rate (% of runners who started the race) in 
different groups 
 
Six thousand five hundred and thirty-five (6535) runners of the 7035 runners in 
this cohort started the race. Of these runners who started, 6413 runners (98.1%) 
finished the race and 122 runners (1.9%) did not finish. Of the 122 runners who 
did not finish, 96 runners did not report any symptoms during the 7 days prior to 
the race, while 26 runners did report symptoms of an acute illness in the 7 days 
prior to the race. 
 
The did-not-finish (DNF) rate (% runners) in different groups and sub-groups is 
depicted in Table 3.3. The DNF rate for the control group (asymptomatic runners) 
(1.8%) was similar to that of the symptomatic group (2.2%) (p=0.3778).  
 
Runners who experienced systemic symptoms in the 7 days prior to the race had 
the highest DNF rate (2.7%) (p=0.1954 vs. control), followed by the runners who 
experienced gastrointestinal symptoms during the 7 days prior to the race (2.3%) 
(p=0.16 vs. control) and runners who experienced respiratory symptoms (1.8%) 
(p=0.9571 vs. control). Runners in the failed “neck check” group had a DNF rate 












Table 3.3. The did-not-finish (DNF) rate (% runners who started the race) in 
different groups and sub-groups 
 
Group Sub-group Percentage of 
runners 
P-value * 
Control group  1.8%  

























*: p value vs. control group 
 
3.4.4. The medical complication (MC) rate (% runners who started the race) 
in different groups 
 
Of the 6535 runners who started the race, 16 runners were admitted to the 
medical facilities during the race, while 6519 runners did not need medical 
attention. Of the 16 runners who required medical attention, 12 runners did not 
report any pre-race symptoms of an acute illness, while 4 runners reported 
symptoms of an acute illness in the 7-day period prior to the race. 
 
The medical complication (MC) rate (% runners) in different groups and sub-
groups is depicted in Table 3.4. The MC rate of the control group was 0.22% and 
that of the symptomatic group was 0.34%, but this was not significantly different 
between the two groups (p=0.4844). The MC rate of the runners who passed the 
“neck check” was 0.24% and the rate for the runners who failed the “neck check” 
was 0.26% (p=0.9306). The runners who experienced systemic symptoms during 
the 7 days prior to the race had a MC rate of 0.44% (p=0.3782). 
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Table 3.4. The medical complication (MC) rate (% runners who started the 
race) in different groups and sub-groups 
 
Group Sub-group Percentage of 
runners 
P-value * 
Control group  0.22%  



















*: p value vs. control group 
 
3.4.5. Summary of the main outcome variables 
 
A summary of the main outcome variables in the symptomatic and control group 
is depicted in Table 3.5. The DNS rate was significantly higher in the 
symptomatic group compared with the control groups, while the DNF and MC 
rates were similar between the two groups. 
 








DNS rate 6.23% 10.84% <0.0001 
DNF rate 1.8% 2.18% 0.3778 









The main findings of this study were as follows: 1) 19.2% of runners in this cohort 
reported symptoms of an acute illness in the 7-day period prior to an endurance 
race, 2) the most common symptoms of acute illness were sore throat (34.5%), 
runny nose (29.9%), general tiredness (27.8%), blocked nose (23.3%) and 
headaches (22.6%), 3) 12.7% of runners reported acute respiratory symptoms, 
7.5% of runners reported acute systemic symptoms, and 3.5% reported acute 
gastrointestinal symptoms, 4) 12.5% of runners reported symptoms that would 
result in a failed “neck check”, 5) runners who reported symptoms of acute 
illness, and who were given educational information, had a significantly higher 
did-not-start (DNS) rate compared with control (no reported symptoms) runners, 
6) runners who reported symptoms of acute illness, and who were given 
educational information but decided to start the race, had a similar did-not-finish 
(DNF) rate compared to control runners, and 7) runners who reported symptoms 
of acute illness, and who were given educational information, but then decided to 
start the race had a similar medical complication (MC) rate compared to control 
runners.  
 
3.5.1. Period prevalence of runners with symptoms of an acute illness 7 
days prior to the race 
 
In this study, 19.2% (N=1338) of runners reported one or more symptoms of an 
acute illness in the 7 day period prior to the race. This percentage is lower than 
the 40% of athletes who reported an episode of an URT illness in the 8 week 
period prior to the 1987 Los Angeles Marathon (14), but is similar to the 17% of 
runners who reported symptoms of an infectious episode in the 3 week period 
prior to the 2000 Stockholm Marathon (18). However, a strict comparison with the 
prevalences is not valid because different definitions of illness were used, and 
the period (1 week, 3 weeks and 8 weeks) differs between studies. However, 
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these data do indicate that a significant percentage of runners experience 
symptoms of acute illness in the 1-8 weeks prior to a race. 
 
In our study, the most common symptom indicated by the symptomatic group 
(N=1338) was a sore throat followed by a runny nose, general tiredness and a 
blocked nose. Symptoms of an acute respiratory illness were therefore most 
common. These data are consistent with many studies showing that acute 
respiratory illness is the most common acute illness in athletes before and during 
competition ((1), (5), (6), (7)). Therefore the most common illnesses amongst 
runners are acute respiratory conditions (URT illness), followed by 
gastrointestinal disorders and then dermatological conditions.  
 
However, in our study we note that 8% of runners reported a fever, 12.7% 
symptoms of an acute systemic illness, and 12.5% reported symptoms that 
would constitute a failed “neck check”. These data are of concern as systemic 
illness can affect a number of organ systems including skeletal muscle (myositis) 
and the cardiac muscle (myopericarditis) ((1), (3), (8)). These runners may 
therefore be at a particular risk of developing medical complications (including 
life-threatening complications) during a race. It is for this reason that we included 
an educational intervention program, as part of this study, to inform runners of 
the potential medical complications that may result from exercising while 
suffering from an acute systemic illness. 
 
3.5.2. Did-not-start (DNS) rate 
 
It is well established, from data obtained through the race organisers, that a 
percentage of runners who enter for a race, complete the registration process in 
the days prior to the race, still elect not to start the race on race day. We 
recognize that there are many possible reasons for this. However, in this study, 
we provided all the runners in our cohort of 7035, who reported symptoms of an 
acute illness in the 7 days before the race, with targeted educational information 
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and guidelines for safe participation when they suffer from acute illness. In our 
study the DNS rate was significantly higher in the symptomatic group (10.8%) 
compared to the control group (6.2%). On the assumption that all the other 
possible factors that could influence runners in a decision to not start the race 
were similar between the two groups, we conclude that the higher DNS rate in 
the symptomatic group was as a result of the educational information that was 
provided. We cautiously conclude that the educational information was effective 
in increasing the DNS rate in runners with more severe illness that could lead to 
a potential medical complication. In particular, we note that in sub-groups with a 
potential higher risk for medical complications the DNS rate was higher: systemic 
symptom group (14.7%), failed “neck check” group (12.2%), and gastrointestinal 
symptom group (12.1%). It is well established that clinical guidelines consistently 
report that systemic symptoms is a contraindication to participate in sport ((2), 
(3), (8), (12), (15), (30)).  
 
These data indicate that an acute pre-race illness screening process can identify 
runners with acute illness symptoms, that educational intervention can be 
applied, and this is related to an increased rate of deciding not to start a race. 
However, we did not have a group of runners in our study with reported 
symptoms but who did not receive educational information as a comparison. The 
inclusion of such a group in our study was not possible for ethical reasons. 
Therefore, we cannot attribute the increased DNS rate solely to the screening 
and educational intervention program. It is for this reason that we wanted to track 
runners that made the decision to start the race and determine whether the did-
not-finish and the medical complication rates were different in the symptomatic 
and control groups. 
 
3.5.3. Did-not-finish (DNF) rate and the medical complication (MC) rate 
 
The main finding in the DNF rate was that this was similar in the control group 
(1.8%), the symptomatic group (2.18%) and the sub-groups within the 
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symptomatic group: systemic symptom group (2.7%), respiratory symptom group 
(1.8%), gastrointestinal symptom group (2.3%), and the failed “neck check” group 
(2.2%). Similarly, the MC rates in the control group (0.22%) was similar to that in 
the symptomatic group (0.34%). 
 
These data indicate that runners who reported pre-race symptoms of acute 
illness, and who then received educational information, and then decided to start 
the race, did not have a higher rate of not finishing the race or developing 
medical complications. We acknowledge that factors other than the information in 
the educational intervention could contribute to the decision to not start the race. 
However, as mentioned it appears that the screening and educational information 
did increase the DNS rate, and that those runners who did start the race despite 
pre-race illness did not have an increased rate of not finishing or developing 
medical complications. 
 
However, we do note that the MC rate in the sub-group of runners with systemic 
symptoms, was 0.44% and that this rate was higher than the control group and 
the symptomatic group. This was not statistically significant, and we note that this 
is perhaps as a result of a small sample size. This requires further investigation 
and a larger prospective cohort study. 
 
In summary, when the results of the DNS rate, DNF rate and MC rate are taken 
into consideration, it appears that the screening and educational intervention 
prior to the race (information leaflets) resulted in an increase in the DNS rate, 
and that this “filtered” higher risk runners from those at lower risk of not finishing 
or developing medical complications during the race (similar DNF and MC rates). 






3.5.4. Strengths and limitations of the study 
 
The main strengths of our study are that it is novel, that we screened a large 
number of runners, and that we were able to track the cohort accurately and 
successfully during the race period. However, our study also had some 
limitations. We were not able to obtain data from all runners who entered the 
race and had a modest response rate of 27.6%. However, this limitation would 
only affect the accuracy of the prevalence data, and would not affect the impact 
of the screening and educational intervention as the compliance to follow-up of 
the final cohort was 100%. We also acknowledge that there was no clinical 
diagnosis made on the ill runners and the data captured relied on self-reported 
symptoms by the runners. It is thus possible that some symptoms reporting was 
inaccurate, for example, a sore throat and runny nose could have been due to 
allergies as opposed to an infection, and generalised body pains and tiredness 
could have been due to a chronic condition and not due to an acute illness. We 
also acknowledge that in our control group some runners might not have 
reported symptoms. Finally, as previously mentioned, we do not know all the 
possible reasons for runners not starting or not finishing the race. We can 
therefore not assume that the DNS, DNF and MC rates were only as a result of 
an acute illness, or subsequent advice given to them through the educational 
intervention. In future studies, data to determine the precise reasons for not 
starting or not finishing should be obtained from runners. 
 
3.6. Summary and conclusion 
 
It has been well established that the most common acute illnesses affecting 
athletes are URT illnesses, with the prevalence varying in studies from 17% to 
40%. In our cohort of 7035 runners, 1138 runners (19.02%) experienced 
symptoms of an acute illness in the 7-day period prior to the race. The most 
common symptoms experienced were that of an acute respiratory illness 
(12.7%), followed by symptoms of a gastrointestinal illness (3.5%). Five hundred 
 94 
and thirty (530) runners (7.5%) experienced symptoms of an acute systemic 
illness, while 878 runners (12.5%) failed the check. 
 
The did-not-start rate for the symptomatic group was 10.8%, which was 
significantly higher than the DNS rate of the control group (6.2%). The DNS rate 
for the runners with systemic symptoms was highest at 14.7%, whilst the DNS 
rate for the runners who failed the “neck check” was 12.2%. Both these groups 
DNS rates were also significantly higher than the control group. It is thus clear 
that those runners who reported symptoms of acute illness, and who were given 
educational information, had a significantly higher DNS rate compared with the 
control runners. We thus conclude that the higher DNS rate in the symptomatic 
group was as a result of the educational information that was provided and we 
cautiously conclude that the educational information was effective in increasing 
the DNS rate in runners with more severe illness that could lead to a potential 
medical complication. 
 
The DNF rate for the symptomatic group was 2.2%, which was similar to that of 
the control group, which was 1.8%. Runners who experienced systemic 
symptoms in the 7 days prior to the race had the highest DNF rate (2.7%), whilst 
runners who failed the “neck check” had a DNF rate of 2.2%. Similarly, the 
medical complication rate did not differ much between the control group (0.22%), 
the symptomatic group (0.34%), the systemic symptom group (0.44%) and the 
group who failed the “neck check” (0.26%). From these data, it is clear that 
runners who reported symptoms of acute illness, and who were given 
educational information but decided to start the race, had a similar DNF rate and 
MC rate compared to control runners. From this we conclude that runners who 
reported pre-race symptoms of acute illness and who received educational 
information, and then decided to start the race, did not have a higher risk of not 
finishing the race or developing medical complications. Runners who decided to 
run despite their symptoms of acute illness, made the correct decision with the 
help of the guidelines provided. 
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Our study thus indicates that a screening process can identify runners with acute 
illness symptoms, and that educational intervention can be applied and this is 
related to an increased rate of not starting a race, no increase rate of not 
finishing the race, and no increased medical complication rate. From a practical 
clinical point of view, the screening and educational interventional program made 
it safer for the runners to participate in the endurance race. Perhaps further 
studies should be done on even larger cohorts to validate our findings, after 











Summary and conclusion 
 
4.1. Summary of main findings 
 
The focus of this dissertation was acute illness in athletes, particularly focusing 
on acute illness in endurance runners in the 7-day pre-race period, how illness 
affects the decision to participate, and the ability to finish a race without medical 
complications. The feasibility and what impact a screening process and 
educational intervention guideline program would have on making the race safer 
for athletes with an acute illness was studied. 
 
In Chapter 2, the period prevalence of runners with an acute illness one week 
prior to an endurance race was firstly reviewed. There were only 2 studies 
conducted to ascertain such a period prevalence, but the periods were 2 months 
prior to a race and 3 weeks prior to a race respectively. From an epidemiological 
perspective, the review indicated that an URT infection was the most common 
illness amongst athletes, followed by gastrointestinal disorders and 
dermatological conditions. However, the researchers utilized self-reported 
questionnaires in these studies, and a clinician never made a diagnosis of an 
URT infection. As such, other causes for URT illness symptoms in athletes needs 
to be considered, such as allergic rhinitis. It is however well documented that 
exercising with an acute illness is not without risk and potential medical 
complications include myocarditis, rhabdomyolysis with acute kidney failure and 
sudden cardiac death. Infections, including URT infections, also have an 
influence on several systems in the body, including the cardiovascular, 
neurological and muscular systems, thermoregulation and metabolic processes. 
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These effects all culminate into a negative effect on the athlete’s exercise 
performance.  
 
The review further indicated that there are very little data available to validate the 
“neck check” (safe to exercise with local URT symptoms and unsafe to exercise 
with systemic symptoms or lower respiratory tract symptoms) as a clinical 
guideline to advise an acutely ill athlete on participation in an exercise session or 
race. The value of ascertaining the influence of an intervention educational 
program (guidelines based on the “neck check” and various available return-to-
play guidelines) on the safe participation of acutely ill runners was again 
confirmed. Finally, the review also showed that there is no evidence in the 
literature pertaining the DNS rate or the DNF and MC rates of runners after an 
acute illness screening process has been completed. With these questions in 
mind, the original research component was undertaken. 
 
The research study in this dissertation was conducted on a cohort of 7035 
runners. In this cohort, the period prevalence of runners with an acute illness in 
the 7-day period prior to the race was 19.02%, and the most common symptom 
experienced by the runners was a sore throat, followed by a runny nose. These 
findings support the evidence in the literature that an URT illness is the most 
common illness amongst endurance athletes. In the control group (asymptomatic 
runners) 6.2% of the registered runners did not start the race (DNS rate), and this 
was significantly lower than the DNS rate for the runners with acute illness 
symptoms who then received educational material as an intervention (10.8%).  
The DNS rate for the runners with systemic symptoms was highest (14.7%) and 
this was significantly higher than the control group, as was the DNS rate for the 
runners who failed the “neck check” (12.2%). We suggest that the higher DNS 
rate in the symptomatic group was (in part) as a result of the educational 
information that was provided. We cautiously conclude that the educational 
information was effective in reducing the number of runners with an acute illness 
to start the race. Furthermore, runners with more severe illness (systemic 
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symptoms) also withdrew from running on race day, thereby reducing the risk of 
a potential medical complication. 
 
The DNF rate for the symptomatic group was 2.2%, which was similar to that of 
the control group (1.8%). Runners who experienced systemic symptoms in the 7 
days prior to the race had the highest DNF rate (2.7%) and runners in the failed 
“neck check” group had a DNF rate of 2.2%. Similarly, the MC rate of the control 
group was 2.2%, which was similar to the MC rate of the symptomatic group 
(0.34%), the failed “neck check” group (0.26%) and the group who had systemic 
symptoms (0.44%). These data indicate that runners who reported pre-race 
symptoms of acute illness and who received educational information, and then 
decided to start the race, did not have a higher risk of not finishing the race or 
developing medical complications. These data provide the first evidence that a 
screening and educational information program for acute illness can increase the 
DNS rate, and therefore those runners who did start the race despite pre-race 
illness, did not have an increased risk. These data are novel, and we do not have 
similar studies for comparison.  
 
4.2. Clinical implications of findings 
 
As we cautiously conclude from our study that the screening and educational 
intervention program led to a higher DNS rate in the symptomatic group and in 
runners with more severe illness that could lead to a potential medical 
complication, and as the data indicated that those runners who did start the race 
despite pre-race illness did not have an increased risk, we make the following 
suggestions:  
1. In future, all athletes could be screened for an acute illness prior to an 
endurance race and given appropriate educational material. 
2. Social media could play an important role in this process. 
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3. Athletes with symptoms of an acute illness should receive education, in 
the form of a leaflet, pertaining their illness. This information leaflet should 
have the contraindications for exercising on them. 
4. A medical facility could be made available at the registration venue where 
athletes can go for a medical check-up if they are uncertain whether to 
participate in the race. This process should include a physical 
examination, as some symptoms of an URT illness are due to causes 
other than infection. 
5. Athletes should be educated on possible medical complications when they 
exercise, in particular when exercise is contraindicated so that they 
understand the risks involved and can make an informed decision on 
participation.  
 
4.3. Suggestions for further research 
 
We suggest that further research be conducted in this area, particularly an 
extension of this study with a larger sample size. The following areas for 
research should be considered in a larger cohort: 
1. Other possible reasons (i.e. not due to the educational intervention 
program or due to illness) for the did-not-start rate. 
2. Other reasons (i.e. not due to illness) for the did-not-finish rate. 
3. Possible medical complications that only developed later (i.e. a couple of 
hours or of day after the race), such as rhabdomyolysis. 
4. Our screening process relied on self-reported symptoms and it is thus 
possible that some diagnosis of an “acute illness” could indeed have been 
a non-infective condition, such as an allergy. Future studies should include 
a physical examination, and possibly special investigations, to make a 
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Pre-race questionnaire  
Email to runners 
 
Subject of email: Your Old Mutual Two Oceans Marathon: Important information 
 
Dear [insert name] 
Congratulations for coming this far!  It is only a few days to go before your race. We 
trust that your training and preparation has been going well.  
Here is your final medical check list before race day: 
 
Final medical checklist for [Insert name]  
1. Completed medical questionnaire on entry– Yes 
2. Received medical information in newsletters – Yes 
3. Medical information in the race magazine – Please read 
4. Medical aid and next of kin details on your race number – Please complete after 
registration 
5. Last minute information about running and flu/infections – Please click here to 
answer a single question 
 
We wish you all the best for the race. 
 
The Two Oceans Medical team 
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Running and symptoms of an acute infection 
 
Symptoms of acute illness and infections such as flu, gastro-enteritis (upset stomach) 
and other infections (e.g. bladder) are more common in runners just before a race 
(after periods of peak training). Running with symptoms of an infection can increase 
the risk of medical complications during the race. 
The symptoms of infections vary but include the following: generally not feeling well, 
fever, general muscle pain, general joint pain, general tiredness, headache, sore 
throat, blocked or runny nose, sore ears, cough, wheeze, diarrhoea, nausea, vomiting, 
or abdominal cramps/pain.  
Please answer the following question so that we can give you advice: 
 
Do you have any of these symptoms of acute illness (today or in the last 7 days) 
No      

















Question 2: Symptoms of an acute infection or illness 
Symptoms of an acute infection or illness 
 
You indicated that you have symptoms of an acute illness 
(today or in the last 7 days)  
 
Please indicate which symptoms do you have?  
(Please tick on all the symptoms you have i.e. you may 
chose more than one) (Based on your responses, you will be 
sent some information to assist you)  
 Fever    
 Sore throat 
 Runny nose    
 Blocked nose 
 Sore ears 
 Wheezing    
 Cough 
 General muscle pains  
 General joint pains 
 Headache      
 General tiredness 
 Nausea    
 Vomiting 
 Diarrhoea 
 Abdominal pain or cramps          
 Skin rash / infection 
 Symptoms of a bladder infection 























Information leaflets  
Guidelines 
Running and respiratory tract infections 
(“flu” and “common cold”) 
 
Respiratory tract infections are the most common infections of affecting athletes 
and are caused by viruses (mostly), bacteria or other organisms. However, 
symptoms of respiratory tract infections may also be caused by a non-infectious 
cause such as an allergy. These infections mainly affect the nose, sinuses or 
throat area and are then known as upper respiratory tract infections.  
Symptoms of an upper respiratory tract infection are blocked nose, runny nose, 
sore throat, and painful sinuses. Usually, but not always, these infections result in 
no symptoms affecting the whole body (fever, muscle pain, joint pain, general 
tiredness).  
If the infection spreads to the airways and lungs this is known as a lower 
respiratory tract infection. Typical symptoms of a lower respiratory tract infection 
are cough, chest pain, and shortness of breath. Usually, but not always these 
infections are associated with symptoms affecting the whole body (fever, muscle 
pain, joint pain, general tiredness). 
 
Running and respiratory tract infections 
Taking part in exercise while having an infection can be very detrimental to your 
health and can cause serious complications. Some of the viruses can affect the 
heart muscle (known as myocarditis), resulting in heart muscle damage and even 
sudden cardiac death. Please remember that other infections, such as measles 
and chickenpox affect the respiratory tract and your whole body. They are 
contagious and it is recommended that you do not exercise when you suffer from 
these illnesses.  
There are very strict guidelines to assist you in preventing complications during 
running when you have symptoms of a respiratory tract infection.  
Please take note that if you have any of the following symptoms of respiratory 
tract infections, it is recommended that you do NOT take part in exercise: 
 Fever 
 General muscle pains 
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 General joint pains 
 Chest pain 
 Increase in your resting pulse rate 
 Shortness of breath (more than usual) 
 General tiredness (fatigue) that is more than usual 
 Severe sore throat 
 Swollen and painful lymph nodes in your neck 
If you have any of these symptoms we suggest that you do NOT train or race, 
and consult your doctor for further advice and treatment. 
At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and respiratory tract infections. 
 
When can you resume running after a respiratory tract infection? 
It is suggested that you can return to running after a respiratory tract infection 
only when all your symptoms have disappeared and you feel well again. If you 
are not sure, please have an evaluation by a qualified medical doctor. In some 
mild cases where your symptoms are only in the upper respiratory tract (no 
generalized body symptoms) your doctor may allow some form of low-moderate 
intensity exercise. 
 
Two Oceans Medical Team 
 




















Running and acute infections 
Runners that are training very hard may be more susceptible to acute infections. 
Therefore, at the peak of your preparation for the race you may have symptoms 
of an acute infection. These vary according to the body system that is affected 
but the common general symptoms of an infection are: fever, headache, general 
body aches and pain, and excessive tiredness (malaise). Depending of the body 
part that is affected, other symptoms may also be present.  
If you have symptoms of any acute infection (including bladder infections, skin 
infections etc.), especially in the week before the race, we strongly urge you to 
seek a medical opinion from a qualified medical doctor.  
Taking part in exercise while having an infection can be very detrimental to your 
health and can cause serious complications. Some of the infective agents 
((viruses or bacteria) can, for example, affect the heart muscle (known as 
myocarditis), resulting in heart muscle damage and even sudden cardiac death. 
There are very strict guidelines to assist you in preventing complications during 
running when you have symptoms of an infection.  
Please take note that if you have any of the following symptoms of an infection, it 
is recommended that you do NOT take part in exercise: 
 Fever 
 General muscle pains 
 General joint pains 
 Chest pain 
 Increase in your resting pulse rate 
 Shortness of breath (more than usual) 
 General tiredness (fatigue) that is more than usual 
If you have any of these symptoms, or other symptoms of an infection, we 
suggest that you do NOT train or race, and consult your doctor for further advice 
and treatment. 
At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and infections. 
 
Two Oceans Medical Team 
 






Running and gastro-enteritis (gastro-intestinal 
infections) 
 
Gastro-enteritis (including gastro-intestinal infections), is very common in 
athletes, particularly when travelling. The causes of gastro-enteritis can be as a 
result of an infection or a toxin (“food poisoning”). The typical symptoms of 
gastro-enteritis are nausea, vomiting, diarrhoea and abdominal cramping (pain).  
Acute gastro-enteritis can have detrimental effects on your ability to run, largely 
as a result of dehydration and electrolyte disturbances. Symptoms affecting your 
whole body such as fever, muscle pain, joint pain, and general tiredness may 
also occur.  
There are very strict guidelines to assist you in preventing complications during 
running when you have symptoms of gastro-enteritis.  
Please take note that if you have any of the following symptoms of gastro-
enteritis, it is recommended that you do NOT take part in exercise: 
 Fever 
 General muscle pains 
 General joint pains 
 Dehydration (dizziness when standing, decreased urine volume and 
concentrated urine, thirst, dry mouth and decreased saliva production) 
 On-going nausea and vomiting 
 On-going abdominal cramps  
 Increase in your resting pulse rate 
 General tiredness (fatigue) that is more than usual 
If you have any of these symptoms we suggest that you do NOT train or race, 
and consult your doctor for further advice and treatment. 
At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and gastro-enteritis. 
Two Oceans Medical Team 
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